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CHAPTER 1
Introduction
Epilepsy is a disease defined by the presence of recurrent seizures, where a
seizure is a period of excessive, synchronous neural activity in the brain. Symptoms of
seizures vary depending on the location of the initiating site (seizure focus) and whether
it spreads across other areas of the brain, but can range anywhere from brief staring
episodes (‘absence seizures’) to sensing unusual odors to death from sustained,
generalized convulsions. As most types of seizures involve a loss of consciousness, even
mild forms of epilepsy are debilitating for patients since they prevent many common
daily activities such as driving a car or bathing alone. Epilepsy is also one of the most
common neurological disorders occurring in up to 1.0% of the world population (1).
Approximately two million people in the United States have epilepsy and three percent
will develop epilepsy at some point in their lives.
Despite epilepsy’s prevalence, severity, and the fact that it has been recognized
for millennia (2), very little is known about its underlying cause. While single gene
defects in ion channels or neurotransmitter receptors are associated with some forms of
inherited epilepsy (3-5), these mutations account for only a very small proportion of
epilepsy cases. Most cases of epilepsy result from a focal brain region of enhanced
excitability, which can depolarize rhythmically and cause excitability to spread through
the brain, leading to generalized convulsions.

Nearly any type of brain lesion can

produce epilepsy, including trauma, tumor, and cerebrovascular disease, but there is often
no consistently identifiable pathology (6). The heterogeneity of causes, combined with
the fact that most cases have no discernable etiology, have made studying and treating the
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disease difficult.

Current pharmacological treatments for epilepsy target only the

symptom of seizures in a general manner, but do not address the underlying brain
abnormality that generates them (7). This means that patients must be on medications for
life, often with severe side-effects due to their lack of specificity for the epileptic areas of
brain. In approximately 30% of patients, even these medications cannot adequately
reduce their seizure frequency (8).
In recent years, electrical mapping and imaging techniques have allowed for
surgical resection of epileptic foci in patients with intractable epilepsy which does not
respond to medications. Resection is often curative (9), which implies a fundamental
difference between regions that initiate seizures and nearby areas that do not. Although
there are numerous causes of epilepsy, all cases exhibit a similar syndrome of increased,
coordinated activity, so there may in fact be a final, common, causal pathway. With this
in mind, previous studies in our laboratory compared gene expression levels between
areas of seizure onset and areas not involved in seizures within individual patients
(10,11).

When these results were compiled across multiple patients with different

etiologies, a group of approximately 140 genes were found to be commonly differentially
expressed at seizure onset zones, no matter what originally caused each patient’s
epilepsy. Further, many of these genes were localized to cortical layers II and III, and
synaptic density was increased in these layers as well. Discovery of these common
molecular changes will allow animal models of epilepsy to be verified as true molecular
mimics of the human disease so that targeted therapies developed in them are more likely
to translate into viable treatments.
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Interictal spikes in human epilepsy
In patients with epilepsy, abnormal electrical discharges occur between seizures,
referred to as “interictal spikes”. These interictal spikes are small, abnormal discharges
from focal areas of brain.

Like seizures, they are the product of a population of

inappropriately-synchronized neurons firing together. Unlike seizures, they do not spread
across large areas of the brain and do not cause any recognized symptoms. However,
because interictal spikes occur much more often than seizures and develop long before
actual seizures, there has been a growing interest in the molecular roles of interictal
spiking in epilepsy (8). The relationship of interictal spikes to seizures is still
controversial, as they increase in frequency after rather than before seizures (12-15).
Still, they are most frequent in the areas of brain that initiate seizures in a majority of
patients, and are used to identify epileptic brain regions for resection surgeries (16-23).
Some studies have shown that removing areas of high spike activity in the temporal lobe
is associated with good surgical outcome (19,24,25). Furthermore, a recent double-blind
study that used add-on therapy to reduce interictal spiking showed behavioral
improvements in patients with epilepsy, raising the possibility that interictal spiking itself
is deleterious to normal brain functioning (26).
These observations suggest that interictal spikes play an important role in human
epilepsy, yet reveal the paucity of knowledge about them. One of the reasons interictal
spikes have been so poorly studied is the difficulty and subjectivity involved with
quantifying

them.

Spikes

are

typically

marked

manually

by

trained

electroencephalographers, but thousands of spikes can occur in just a 10-minute
intracranial electroencephalogram (EEG) sample and there is no strict definition of a
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spike on intracranial EEG (27-30). Additionally, spiking patterns within the same patient
vary greatly over time, so a tremendous amount of EEG would need to be reviewed to
gain an accurate picture of spiking in each patient (17). A more objective, automated
method of spike detection would solve these problems and allow better studies of
interictal spiking. Studies based on a reliable detection method might reveal important
characteristics of interictal spiking that have previously been masked by reviewer
variability.
Despite these limitations, previous work in our laboratory supports an important
role for interictal spikes in epilepsy. In Rakhade 2007 (31), it was shown that expression
levels of several genes induced in epileptic regions of brain correlated precisely with the
frequency and amplitude of interictal spikes measured in the regions of cortex from
which the samples were taken.

No such correlation was found for any aspects of

seizures, such as frequency, duration or type. These results suggest that interictal spikes
may be able to induce activity-dependent gene expression, and may be necessary for
either creating or maintaining an epileptic focus. Experiments to determine whether this
is actually true would have to be carried out in an animal model, however.

Animal models of epilepsy and interictal spikes
Animal models have been used to investigate epilepsy for decades (32), and most
of them have been reported to generate interictal spikes in addition to seizures. Rarely,
however, are interictal spikes the focus of study and their contribution to both pathology
and epileptogenesis is difficult to disentangle from that of seizures. An ideal model for
the study of clinically-important interictal spikes in animals would be to mimic the
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human phenomenon as closely as possible. This would require interictal spikes in the
absence of frank seizures that are similar to those observed in humans, are chronic,
spontaneous, and are not associated with significant neuronal toxicity or death.
Both acute and chronic interictal spikes have been observed in animal models. In
hippocampal slice culture, gamma-aminobutyric-acid-A (GABAA) blockade (33-35), low
extracellular magnesium concentration (36), low extracellular calcium (37,38), kainic
acid (39,40), and 4-aminopyridine (41) have all been used to generate interictal-like
activities (42). The advantage of these methods is that interictal activity without ictal
discharges can be generated in order to study the electrophysiological properties of
interictal spikes independently from seizures. Disadvantages are that the relationship of
in vitro discharges to those generated in intact animals is unclear and nothing can be said
about ‘higher order’ phenomena such as behavior with in vitro models. Acute in vivo
models are better suited to address these problems. Systemic administration of GABAblocking substances, kainic acid, or pilocarpine produces interictal spikes, but these can
also be injected focally. After penicillin injection into the cortex, focal interictal spikes
as well as seizures occur and can last for six to eight hours (43-45). Kainic acid or
pilocarpine given systemically produce acute status epilepticus that can last for several
hours, after which interictal spikes are observed (46-51). Pentylenetetrazol is generally
used as a convulsant agent, but in the right dose can produce spikes with no detected
seizures and produces minimal tissue damage (52). One question that remains with all of
these acute models of epileptiform activity is whether they are truly identical to the
spontaneous interictal spikes generated chronically in patients with epilepsy.
Chronic models of epilepsy are generally produced by an initial lesion, followed
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by a latent period, and the subsequent development of spontaneous epileptiform activities
(42). Most models focus on the hippocampus, and commonly used methods of modeling
human hippocampal epilepsy are electrical kindling, or systemic administration of
pilocarpine or kainic acid. Kindling involves repeated electrical stimulations which cause
seizures. If done enough times, kindling can lead to the production of spontaneous
interictal spikes and seizures (12,53,54). Status epilepticus induced by either pilocarpine
or kainic acid causes significant neuronal damage in the hippocampus, but after a latent
period, large interictal spikes mixed with spontaneous seizures occur chronically in a
subset of animals (46-51).

For chronic neocortical epilepsy, the most common

techniques are application of either toxic metals or tetanus toxin. When metals, such as
cobalt, are directly applied to the cortex, spontaneous interictal and ictal activities are
observed and can persist for one or more weeks, depending on the method of application
(12,53,54).

Limitations of using metals are that the epileptiform activity requires

continued presence of the irritant and extensive tissue destruction is seen at the site. This
is likely different than lesions that produce epileptic foci in humans, such as brain injury,
which are usually single, initial insults (1,55,56).
Tetanus toxin injected directly into either the neocortex or hippocampus produces
a variety of transient excitatory patterns dependent on the injection site (57-60). It is a
good model of chronic epilepsy because it does not produce significant neuronal toxicity
as many of the other focal models do and does not produce the tissue destruction
observed after prolonged status epilepticus. Tetanus toxin preferentially binds to the
gangliosides of inhibitory neurons, where it is taken up by receptor-mediated endocytosis
and cleaves synaptobrevin (VAMP-2), which prevents the release of vesicles containing
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inhibitory neurotransmitters (61-63). An initial injection of tetanus toxin is followed by a
latent period, after which interictal spikes and spontaneous seizures can persist almost
indefinitely (>7 months) (60,64,65). Most intriguingly, Brener et. al. noted that, unlike
injections into hippocampus or motor cortex that produce seizures early on, injection of
small amounts of tetanus toxin into the somatosensory cortex results predominantly in
interictal spikes with only infrequent seizures (60). This model seems to offer the ideal
characteristics to study interictal spikes in animals since it is a chronic, spontaneous in
vivo model, without seizures early on and minimal neuronal cell loss.

Psychiatric and behavioral comorbidities of the interictal state
While interictal spikes do not have any widely-accepted symptoms, epilepsy is
associated with a broad range of comorbid conditions. Patients with epilepsy are more
likely to have attention deficit hyperactivity disorder (ADHD) (66-72), depression
(68,73-78), anxiety disorders (68,73,75,77-79), and other psychiatric conditions
(68,71,78-82). Since these patients are usually in the interictal state between seizures, it
is possible that interictal spikes may contribute to these pathologies. Interictal spikes in
the absence of seizures are not widely thought to have definite symptoms, but they have
not been thoroughly studied and there is some preliminary evidence that they may
actually have subtle effects. Interictal spikes are best studied on intracranial EEG, as
only the largest 1% of spikes are even detectable on scalp EEG (83), but it is clearly
unethical to place intracranial grids on anyone not being considered for epilepsy surgery.
As such, it is very difficult to study interictal spikes in humans outside of their role in
epilepsy.

Nevertheless, EEG abnormalities have been noted in a wide range of
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psychiatric disorders for decades.

In many of these studies, however, all EEG

abnormalities were lumped into a single ‘abnormal EEG’ description and were not
categorized specifically as interictal spikes. Several studies describe a high incidence of
EEG abnormalities in anxiety disorders, panic disorders, and obsessive-compulsive
disorder (84,85).

However, one large community study by Bridgers found that

epileptiform discharges, specifically, were correlated with symptoms of anorexia nervosa,
depression, mania, personality disorders, suicidality without depression, nonpsychotic
explosive behavior, and the effects of psychotropic medications (86).

Individuals

displaying antisocial and aggressive tendencies have also been found to display a wide
range of EEG abnormalities, including epileptiform discharges (87-91). Given the wide
array of psychiatric symptoms and the comorbidity of psychiatric diseases with epilepsy,
long term human recordings and focused behavioral studies in animals will be needed to
establish any causality between these abnormal brain activities and behaviors.
More direct associations of interictal spikes with specific cognitive behaviors
have also been noted on scalp EEG. A recent double-blind study that reduced interictal
spiking using lamotrigine as an add-on seizure therapies showed significant behavioral
improvements in patients with epilepsy raising the possibility that interictal spiking is
deleterious to normal brain functioning (26).

Some studies suggest an association

between high frequency interictal spikes and cognitive and behavioral decline in children
with autism (92,93). Inui, et. al. found that spike variants were significantly higher
among patients with mood-incongruent psychotic mood disorder (33%), schizoaffective
disorder (33%), and schizophreniform disorder (30%) as compared with patients with
nonpsychotic mood disorder (3.2%) and schizophrenia (0%) (94). Interictal spikes have
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even been associated with self-injurious behavior among tuberous sclerosis patients (95).
With a potential role in such a wide range of disorders, it would be advantageous to
develop a better understanding of interictal spikes through animal models.

Genomic perspective on epilepsy
While this project will focus largely on specific protein-coding genes and
pathways in epilepsy, modern techniques now allow for broader analyses to be done,
such as investigating epigenetic modifications, genomic instability and genome-wide
association studies. Many genetic association studies have been conducted in epilepsy,
but most have been underpowered and have not yielded consistent susceptibility genes.
[for review see (96)]. Recently though, results of the first large-scale, genome-wide
association study in epilepsy were released (97). This study compared 3445 patients with
partial (focal) epilepsies to 6935 controls in order to identify common patterns of genetic
susceptibility. Even with a study this large, however, the authors found no significant
genome-wide association and were forced to conclude that common genetic variation
plays only a minor role in predisposition to partial epilepsies. They instead propose that
epilepsy be considered under the “common disease-rare variant” hypothesis (98), where
many rare genetic variants underlie a common disease. Limitations of this study are that
it was carried out in an entirely European population and that types of epilepsy were
ignored. It is therefore possible that a similar study in a different population or which
focuses on a specific type of partial epilepsy may have more success in identifying
common susceptibility variants. Still, these initial results argue against a productive role
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for these types of association studies in epilepsy and leave acquired, focal models of
epilepsy as the best choice for modeling what is known of the human disease.
Epigenetic modifications have been implicated in Alzheimer’s disease (99-102),
Huntington’s disease (103-106), and many other neurological disorders [for review see
(107)], so epigenetics may play a role in epilepsy as well.

The first evidence of

epigenetic involvement in epilepsy came from one of the older anti-seizure medications
still in use today, valproic acid. In addition to enhancing GABAergic function, valproic
acid can also inhibit histone deacetylases (HDACs) at therapeutic concentrations (108).
Kainic acid, one of the most commonly used compounds for modeling epilepsy in
vivo,induces a rapid phosphorylation of histone H3 in dentate gyrus neurons and a more
widespread and sustained acetylation of histone H4 in hippocampal neurons (109,110).
Three hours after the induction of a seizure, histones H4 on the BDNF promoter show
hyperacetylation which correlates with increased mRNA levels. The promoter of the
metabotropic glutamate receptor (GluR2) also shows epigenetic regulation, with histones
H3 and H4 rapidly deacetylated after seizures and corresponding to mRNA
downregulation (111). In the electroconvulsant model of epilepsy, these findings from
the kainic acid model were not only recapitulated, but also showed changes in histones
H3 and H4 on the CREB promoter (112). Given that the few studies investigating
epigenetic modifications in epilepsy thus far have already shown positive results and that
two genes with known alterations in epilepsy, BDNF and CREB, have been implicated,
epigenetics is likely to play an important role in epilepsy and merits further study.
Recent studies have shown that genomic instability, such as copy number variants
(CNVs), are associated with neurological disorders like ADHD (113,114) and autism
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(115), so it is reasonable to conclude that genomic instability may be involved in epilepsy
as well. One large study using Illunima genome-wide genotyping arrays followed by
comparative genomic hybridization (CGH) found deletions at 16p13.11 in 23 of 3812
epilepsy patients, while none of the 1299 controls showed deletions larger than 16kb
(116). Another study identified a microdeletion at 15q13.3 in 12 of 1,223 (1%) of
idiopathic, generalized epilepsy cases using array comparative genomic hybridization
(aCGH) (117) while a different study found this same deletion in 7 of 539 (1.3%) cases
and then showed that it seems to behave as a susceptibility variant (118); it is found in
some but not all family members with epilepsy and some unaffected members also carry
the deletion. The same group then extended their search to additional large, recurrent
microdeletions which were known to occur more frequently in schizophrenia, psychotic
disorder, autism and mental retardation (119).

This study used single nucleotide

polymorphism (SNP) arrays, followed by validation with quantitative polymerase chain
reaction (qPCR) and aCGH, and yielded positive results for the microdeletions at 15q11.2
(12/1234 cases versus 6/3022 controls) and 16p13.11 (6/1234 cases versus 2/3022
controls). Finally, seizures induced in the kainic acid animal model of epilepsy show
instability of the mitochondrial genome (120). In this model, acute status epilepticus
increased oxidative mtDNA damage, which coincided with mitochondrial H2O2
production and a transient decrease in mtDNA repair capacity. In the chronic phase of
this model, up to three months after status epilepticus, mitochondria showed increased
reactive oxygen species production, accumulation of mtDNA damage and impaired
mtDNA repair capacity. Overall, genomic instability does not appear to be involved in
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most cases of epilepsy, but few studies in this area have been done and more prevalent
stability changes may be found in the future.

Project overview
In this project, we first show the high variability between professional reviewers
in marking interictal spikes on intracranial EEG, and then develop and test an automated
detection method to solve this problem. Next, we use this automated detection algorithm
to identify spikes on intracranial EEG in both tumor and non-tumor patients in order to
determine the best spiking parameters to identify the seizure onset zone in each group.
We then develop and characterize an animal model of chronic, neocortical interictal
spiking to test our observations previously made in human epilepsy and to have a
molecularly-accurate model on which to test new therapeutics. Finally, we show that
interictal spikes are associated with behavioral changes in this animal model and that a
targeted inhibitor can both prevent the development of a spiking focus and normalize
behavior.
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CHAPTER 2
High inter-reviewer variability of spike detection on intracranial EEG addressed by
an automated multi-channel algorithm
INTRODUCTION
Interictal spikes are abnormal discharges that occur between seizures in patients
with epilepsy. They are frequently generated in the same regions of the brain that initiate
seizures (16,17), but their exact role in epileptogenesis and the induction or protection
from seizures remains controversial and requires further study. A significant barrier to
such studies comes from the laborious nature of quantifying the thousands of interictal
spikes that can occur in a single recording, and the fact that spiking rates vary greatly
over time (17) within patients, meaning that many samples have to be marked per patient
to get an accurate picture of the spiking pattern. There is also tremendous variability
between EEG reviewers on exactly what constitutes a spike on subdural
electrocorticography (ECoG) (29,121).
To address these issues, we first conducted a study of inter-reviewer variability in
marking interictal spikes in ECoG and, second, compared these results to an automated
spike detection algorithm. While many algorithms have been developed for the detection
of interictal spikes, most are designed for scalp recordings (122), and those few that were
developed specifically for ECoG were either run on single channels or had humans
validate spikes after they were already detected by an algorithm (29,121,123,124). Here,
we validated a novel automatic spike detection algorithm that emulated human reviewing
methods by analyzing multi-channel ECoG sections obtained from 10 patients. We
compared its performance to three independent human reviewers.
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METHODS
Intracranial EEG recordings for this study were obtained from 10 patients
undergoing two-stage surgical resections at the Comprehensive Epilepsy Program at
Wayne State University (#0860000MP2F, Wayne State University Human Investigation
Committee). These patients represent an equal mix of children (8 months-14 years) and
adults (20-54 years), and were selected to include a wide range of activity levels and
spike morphologies. Recordings were obtained with a Stellate Harmonie digital recorder
(Stellate Inc., Montreal, PQ, Canada) sampled at 200Hz, and 10-minute sections were
selected from periods of quiet wakefulness separated by at least six hours from a seizure.
The average number of channels recorded per patient was 95.9 (SD ± 16.5; range 65128). Three trained encephalographers independently reviewed these sections in the same
referential montage (each recording electrode compaired to a single, designated
‘reference’ electrode outside the brain surface). Detections which occurred on the same
channel within 115ms of another reviewer’s mark were taken as detections of the same
spike. This distance was chosen to cover the variation in manual marking of spikes
without picking up marks that may occur on adjacent spikes. The use of distances 10ms
above and below this value produced identical results. As there is no true ‘gold standard’
for comparison, each reviewer was compared to the set of all detections by the other two
reviewers to calculate sensitivity (true positives/(true positives+false negatives)) and
precision (true positives/(true positives+false positives)) for each patient. Finally, we
used each reviewer’s spike detections to generate a ranking of channels from highest
spike frequency to lowest. We then compared these rankings between reviewers in each
patient by calculating Kendall’s coefficient of concordance (W).

Spearman’s rank
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correlation coefficient was also calculated for each reviewer pair, as this is a more
common measure of non-parametric correlation and so human reviewer performance
could be compared to algorithm performance.
The spike detection method was developed as a Matlab program which interacts
directly with the Stellate ECoG files (Algorithm overview in Figure 1A). It extracts
successive one-minute blocks of data from the ECoG recording, with each block
containing the data for all the recorded channels during that minute. First, channels
whose average slopes are more than 10 standard deviations outside the mean for all
channels are eliminated as artifactual, after which the data are bandpass filtered between
20 and 50Hz in order to identify interictal spikes (Figure 1B, Similar to Brown, et al.
2007). Peaks with amplitudes outside four standard deviations of the channel mean are
noted as potential spike locations for further consideration. The original data are then
filtered at 1-35Hz and all channels are scaled by a single scaling factor as an entire block.
This method of scaling all channels as one block was chosen because it most closely
approximates how a human reviewer adjusts sensitivity to review a recording and
because scaling individual channels tends to cause over-marking of less active channels
and under-marking of very active channels (Figure 1C). Once the data have been scaled,
the amplitude and slope of each halfwave of the potential spikes identified previously are
calculated and the values are compared to static thresholds. Waveforms that exceed
amplitude and slope thresholds are marked as interictal spikes. All development and
testing of the algorithm was done on a separate set of ECoG samples from the testing set
used in this study (31).
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Algorithm performance was evaluated both by the ability to correctly identify
individual spikes marked by human reviewers and the ability to correctly rank channels
by spike frequency. We did the same comparison using the commercial spike detector
included with Stellate’s Harmonie software.

Optimal thresholds for each were

determined prior to their use in this study on a different group of patients. Sensitivity and
precision were calculated separately for spikes marked by at least one reviewer, at least
two reviewers, and all three reviewers. To evaluate the performance of the two automatic
algorithms (ours and Stellate’s) in ranking channels by spike frequency, Spearman’s rank
correlation coefficient was calculated between the channel ranking of each method and
the average channel rank from the three human reviewers.
Finally, to determine whether spikes detected by the algorithm but no human
reviewers were truly false positives, ten randomly-selected ‘incorrect’ marks per patient
were later shown to each of the three reviewers who were asked to decide whether these
detected spikes were real or not.

RESULTS
A total of 78,743 spike detections were made by human reviewers from the 10
different patients.

Surprisingly, only 23.7% of these were marked by at least two

reviewers and just 3.1% by all three reviewers (Table 1). Overall, human reviewers
performed poorly in regard to identifying each other’s spikes (Table 2A. Sensitivity:
27.7±12.5%; precision: 50.7±18.5%), but showed good agreement in many (but not all)
patients when simply ranking channel activity from highest to lowest spiking (Table 2B.
Kendall’s W: 0.752±0.12). Spearman's rank correlation coefficient, a similar measure of
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ranking agreement for pairs of data, gave an average value of 0.660±0.02 when
calculated for all reviewer pairs across the 10 patients.
To improve quantitative interictal analyses, we developed an automatic spike
detection algorithm that uses a combination of frequency filtering and examination of
entire blocks of channels (Figure 1).

We compared the performance and channel

rankings to the three human reviewers as well as a commercial spike detection program
included with our EEG software. Consistent with and somewhat better than we found
between reviewers, the algorithm gives an overall average correlation coefficient of
0.750±0.16 for channel ranking, while the commercial detector's was 0.574±0.27 (Table
2B). While the algorithm detected more spikes than any single reviewer (50,315 vs.
39,802 for highest reviewer), it performed with similar sensitivity and precision for each
of the three human reviewers (Table 2C), and yielded better results than the commercial
detector (Table 2D).
To determine whether spikes picked up by the algorithm, but none of the human
reviewers were genuinely false positives or simply missed by the reviewers, 10
randomly-selected spike detections for each of the 10 patients were presented in the
context of the entire recording to each of the three reviewers. They were then asked to
decide whether these detected spikes were real or not. The number of spikes originally
detected only by the algorithm, but then later validated by human reviewers varied widely
among the three reviewers (Table 3, Mean: 31.3±30.4%; Reviewer 1: 65%; Reviewer 2:
6%; Reviewer 3: 23%) This indicates that many of the ‘false positives’ generated by the
algorithm may actually be 'real' spikes.

18

DISCUSSION
This is perhaps the largest study of inter-reviewer variability in the identification
of interictal spikes in intracranial EEG.

There was surprisingly poor agreement

(3.1±2.7%; range 0-7.4% for different patients; Table 1) between three human reviewers
in the identification of specific interictal spikes, despite all being professional
encephalographers and two of them (R1 and R3) training at the same institution. These
results are in line with previous studies which compared reader variability using shorter
files or individual channels (28,121,124-126). While there was significant disagreement
on the identification of individual spikes for a given patient, the reviewers generally
agreed on the ranking of channels by spike frequency.

This is important because

determination of the highest-spiking channels is often the main clinical use for
quantifying interictal EEG.

These findings also underscore the need for automated

methods of spike detection which function reliably across a wide range of ECoG types
(28-30,121).
Our detection algorithm was able to identify spikes with similar sensitivity and
precision as the human reviewers, and did an excellent job of ranking channels based on
interictal spiking activity (Figure 1D, Table 2B). Key advantages to this algorithm are
that it requires no human intervention or tweaking of parameters, is fast enough to be run
‘on-line’ as the ECoG is being recorded, and its performance was validated in a
completely ‘real world’ environment. Previous detection algorithms have been tested
only against a small set of pre-extracted spikes or single channels from each patient,
while here we show that our algorithm performs well when reviewing entire segments in
a way that mimics how a human reviewer would see the ECoG. A reliable spike
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detection algorithm with good agreement between different reviewers could improve both
patient care and research on interictal spiking.
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CHAPTER 3
Morphological parameters of interictal spikes to identify seizure onset zones in
lesional and non-lesional patients
INTRODUCTION
Interictal spikes are often used to assist in the identification of seizure onset zones
for epilepsy resection surgeries. Frequency of spiking is often the main aspect examined,
and while this method has positive results (19,24,25), it is far from perfect. Depending
on the study, the electrode of maximum spike frequency is located in the seizure onset
zone in anywhere from 50-100% of patients examined (16,17,22). In this chapter, we
attempt to improve the ability of quantitative interictal electrocorticography (ECoG) to
identify seizure onset zones by examining how several additional morphological
parameters of interictal spikes relate to seizure onset areas.
Next, we examine the use of electrocorticography and interictal spike detection in
patients with epilepsy caused by brain tumors. Brain tumors are a common cause of
epilepsy in adults, with more than one-third of all adults with brain tumors developing
epilepsy, and more than 50% in cases that involve the cerebral hemispheres (127,128).
Rarely, however, is a two-stage surgery with placement of electrocorticographic grids
done in these patients to identify seizure onset areas.

This is partially due to the

additional stress and invasiveness that would be inflicted on patients who may not have a
good prognosis even after surgery and partially due to an assumption that removal of the
tumor should allow the epilepsy to be cured. If this assumption is not correct though, the
use of intracranial electrocorticography to identify areas of seizure onset outside of the
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tumor may improve outcome in these patients. Further, it may be possible to identify
parameters of interictal spiking which could help detect tumor margins for resection.

METHODS

Patient clinical and electrocorticographical data
Intracranial EEG recordings for this study were obtained from 16 non-lesional
patients and 11 lesional patients undergoing two-stage surgical resections at the
Comprehensive Epilepsy Program at Wayne State University (#0860000MP2F, Wayne
State University Human Investigation Committee). Lesional patients ranged in age from
22-54 years (Mean 40.7±8.5), and included a variety of tumor types (Table 4), while nonlesional patients ranged in age from 17-56 years (Mean 36.7±11.3). The placement of
intracranial grids on lesional patients was a clinical decision and was not influenced by
this study. Recordings were obtained with a 128-channel Stellate Harmonie Digital
recorder (Stellate Inc., Montreal, PQ, Canada) sampled at 200Hz. Recording electrodes
were given one of three “Seizure Categories” by a clinical encephalographer: Seizure
Onset, Seizure Spread, or Control. Seizure Onset zones were identified by sustained
rhythmic changes on EEG that were clearly distinct from background rhythms and
associated with the patient’s seizure type, while Seizure Spread electrodes are those that
pick up these rhythmic discharges within seven seconds of seizure onset.

Control

electrodes are not involved in seizures.
For interictal analysis, three 10-minute sections of ECoG were selected for each
patient from periods of quiet wakefulness separated by at least six hours from a seizure.

22

Interictal spikes were then detected using the automated method validated previously in
Chapter 2. The detected spikes were broken into halfwaves by a Matlab (MathWorks,
R2008b, Natick, MA) script as described previously (31) so that amplitude, slope and
duration could be measured for each halfwave of each spike (Amplitude 1, Duration 1,
Slope 1, Amplitude 2, Duration 2, Slope 2), as well as spike power (frequency *
(Amplitude 1 + Amplitude 2)). The average value of each of these parameters was then
calculated for each channel in a recording and then averaged across the three recordings
per patient.

Three dimensional brain reconstructions and tumor distance calculation
Three dimensional reconstructions of each patient’s brain, including the location
of recording electrodes and tumors if present, were generated from magnetic resonance
imaging (MRI) and computed tomography (CT) scans. These scans were done as part of
normal pre-surgical evaluation and treatment. First, a pre-operative T1-weighted MRI
sequence was imported using BrainSuite09 (David W. Shattuck, Laboratory of
Neuroimaging, UCLA, http://www.loni.ucla.edu/Software/BrainSuite), and the included
tools were used to strip away the skull and leave only the underlying brain. After
creating and exporting a three-dimensional surface rendering of the patient’s brain, this
surface was subsequently imported into the custom software program, Smap (Dr. Jing
Hua and Darshan Pai, Graphics and Imaging Laboratory, Wayne State University
Computer Science Department). Using this software, a post-implantation CT showing
the patient’s electrode grid locations was aligned and coregistered to the pre-operative
MRI. An intensity threshold for the CT was then manually chosen so that only the metal
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electrodes were visible. The software was then able to overlay the CT onto the MRI of
the patient’s brain and extrapolate electrode positions. All electrodes were then manually
verified using intraoperative photographs to ensure correct placement.
In lesional patients, tumor locations were manually outlined on each slice of a
pre-operative MRI by a neurologist, and these markings were then turned into threedimensional renderings by the Smap software. Finally, with the reconstruction of the
patient’s brain, the electrode locations, and the tumor location, linear distance to tumor
was calculated for each electrode in each patient using the Smap software.

Correlation of spiking parameters to seizure category and tumor distance
To investigate which interictal spiking parameters best correspond with seizure
category, morphological parameters of interictal spikes were first normalized to Z-scores
(forcing the data to have a mean of 0 and standard deviation of 1) within each patient so
that the data from multiple patients could be combined. Taking seizure category as an
ordinal variable where Seizure Onset is more ‘epileptic’ than Seizure Spread, which is in
turn more epileptic than Control, we then calculated Spearman’s rank correlation
coefficient for each spiking parameter. The non-normal distribution of the measured
spiking parameters also required us to use the non-parametric Spearman’s correlation for
calculating correlations with tumor distance as well. Correlations with p values greater
than 0.01 after Bonferroni correction for multiple comparisons were discarded.
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Unordered relation of spiking parameters to seizure category and tumor distance
Based on the results of the above study and because the assumption that seizure
category can be treated as an ordinal variable may not be correct, we also examined
whether any of the three seizure category groups differed from each other in terms of
morphological spiking parameters.

Due to the non-normal distribution of data, the

Kruskal-Wallis test was used to look for differences between the seizure category groups.
If this test was significant, it was then followed with a Mann-Whitney U-test to determine
which pairs within the three categories significantly differed from each other.

RESULTS

Correlation of spiking parameters to seizure category
In non-lesional patients, seizure category was significantly correlated (p<0.01
after Bonferroni correction) with five parameters of interictal spiking: frequency,
amplitude of the first halfwave, slope of the first halfwave, amplitude of the second
halfwave and spike power (Table 5). All these correlation coefficients were positive,
indicating that more ‘epileptic’ areas of brain have more frequent, larger and steeper
spikes than more normal areas. In lesional patients, seizure category was positively
correlated with frequency, duration of the second halfwave and spike power. It was
inversely correlated with tumor distance, meaning that brain areas closer to tumors are
more likely to generate seizures.

Correlation of spiking parameters to tumor distance
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Electrode distance from tumor was significantly positively correlated with spike
frequency, duration of the first halfwave, and spike power. It was inversely correlated
with amplitude of both halfwaves and the slope of both halfwaves. Together, these
results would mean that brain areas closer to tumors spike less frequently than farther
areas, but have larger and steeper interictal spikes.

Unordered relation of spiking parameters to seizure category and tumor distance
While the above correlations are statistically significant, the actual correlation
coefficients are extremely small, which casts doubt on their biological relevance. One
issue may be the assumption that the three electrode seizure categories ‘seizure onset’,
‘seizure spread’ and ‘control’ can be treated as ordered. Therefore, we analyzed the same
dataset again, this time treating seizure category as a nominal variable. Significant
results from the Kruskal-Wallis test (non-parametric equivalent of one-way ANOVA)
were followed up with pairwise Mann-Whitney U tests, holding overall α to less than
0.05. Under these conditions, control electrodes in non-lesional patients showed less
frequent spiking, smaller amplitude of both halfwaves, smaller slope of the first halfwave
and less total spike power. In all cases, control electrodes were significantly different
from both seizure onset and seizure spread electrodes, while no difference was seen when
comparing seizure onset to seizure spread electrodes. The similarity of seizure onset to
seizure spread electrodes likely explains the poor values for correlation coefficients seen
previously.
In lesional patients, control electrodes demonstrated a lower spike frequency,
shorter duration of the second halfwave, less total spike power and a greater distance
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from the patient’s tumor. Once again, control electrodes significantly differed from both
seizure onset and seizure spread electrodes, while seizure onset and seizure spread
electrodes never differed from each other.

Best parameters to identify seizure onset zones
A commonly reported measure of the ability of interictal spike frequency to
identify the seizure onset zone is the percentage of patients in which the highest spiking
electrode is contained within the seizure onset area. We therefore conducted this survey
with all the individual parameters in our dataset to see which was most reliably maximal
in seizure onset areas (Table 6). The typical measure of spike activity, frequency, was
maximal in seizure onset electrodes in 4/16 patients, and was never at a minimum in
seizure onset electrodes. Slope of the first halfwave and spike power also identified
seizure onset electrodes in as many patients as spike frequency, while the other
parameters did not perform as well (Figure 2).

These three parameters were also

significantly correlated to seizure category and significantly distinguished control
electrodes from those involved in seizures by the Kruskal-Wallis test, suggesting they
may all be equally good measures of identifying seizure onset zones in non-lesional
patients.
In contrast to non-lesional patients, spike frequency was only maximal in seizure
onset electrodes in 2/11 lesional patients. In this group, duration of the second halfwave
was maximal in seizure onset electrodes in 4/11 patients and was also significant by the
Kruskal-Wallis test.

Adding in the fact that it also had a higher Spearman’s rank
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correlation coefficient to seizure category, duration of the second halfwave is a superior
marker of seizure onset zones to spike frequency in lesional patients (Figure 3).

Seizure onset zones lie outside the tumor area in the majority of patients
While areas near tumors are more likely to be seizure-generating than distant
areas, many patients have additional seizure foci outside the immediate area of the tumor
as well. In 7/11 patients in this study, seizure onset electrodes were located greater than
two centimeters away from the nearest tumor margin, sometimes on entirely different
lobes of the brain (Figure 3). The type of tumor may influence the chance that a seizure
onset zone will occur outside of the immediate tumor area as well, since 4/4 patients with
‘high grade’ tumors (WHO Grade >=3) had distant seizure onset zones, compared to only
3/7 patients with ‘low grade’ tumors (WHO Grade <=2). The small sample number does
not give this study enough power to determine whether a true difference exists though
(p=0.214, two-tailed t-test for difference in proportions). Overall, the average distance to
the farthest seizure onset electrode across all lesional patients was 3.45cm (SD±1.76;
range 1.29-6.86), suggesting that a simple “lesion-ectomy” is unlikely to remove the
entire seizure onset zone in many patients.

DISCUSSION

Seizure onset and spread zones differ from non-epileptic brain
This study showed rather poor correlation between spike parameters and electrode
seizure category.

While statistically significant, the Spearman rank correlation
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coefficients between spiking parameters and seizure category were very low and may not
be biologically relevant. However, this is likely due to seizure category being treated as
an ordinal variable, expecting seizure onset electrodes to be more epileptic than seizure
spread electrodes. Comparing spike parameters between each seizure category showed
that control electrodes consistently differed from seizure onset and seizure spread
electrodes, but onset electrodes did not differ from spread electrodes. In the parameters
examined here then, onset electrodes were not distinguishable from spread electrodes.

Spiking parameters that identify seizure onset zones differ in lesional and nonlesional patients
Putting together the results from the correlations, the Kruskal-Wallis tests, and the
number of patients where highest parameter value was located in a seizure onset
electrode brings out different measures of spiking as best for identifying seizure onset in
lesional and non-lesional patients. In non-lesional patients, frequency, slope of the first
halfwave and spike power all performed similarly and were maximal at seizure onset
electrodes in 25% of the non-lesional patients examined. Although this is poorer than the
rates reported in other recent studies which range from 50-100% (16,17,22), examining a
single electrode per patient is not a terribly robust measure. Interestingly, results from
Spearman correlation and Kruskal-Wallis tests in lesional patients only overlap in spike
frequency and power with non-lesional patients. In lesional patients, duration of the
second halfwave stands out as the best measure for identifying seizure onset areas, with
twice as many patients showing maximal duration in a seizure onset electrode as with
spike frequency. Additionally, the correlation coefficient for duration is nearly twice that
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of spike frequency, again suggesting that this is a better measure in lesional patients than
spike frequency. Quantitative interictal electrocorticography has not previously been
examined in tumor patients, so the results of this study are important because they show
that past research in non-lesional patients cannot necessarily be applied to lesional
patients.

Proximity to tumor is not the best predictor of seizure zones
Perhaps the most interesting result of this study is that areas of seizure onset in
tumor patients are often not directly adjacent to tumors. In most patients (n=7/11),
seizure onset zones exist far from the actual tumor, and this may be more likely in more
aggressive tumors. In fact, duration of the second halfwave was a better predictor of
seizure onset zone than distance from the tumor. The areas immediately surrounding
tumors seem to have low interictal activity as well, with higher spike frequency
correlating well with distance from tumor. These results could help guide the critical
clinical decisions involved in deciding which areas of the brain to resect in tumor patients
with comorbid epilepsy.
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CHAPTER 4
Characterization and pharmacologic inhibition of a neocortical model of interictal
spiking
INTRODUCTION
Previous chapters have focused on interictal spiking in human epilepsy, and prior
studies in our lab have implicated interictal spikes as having a potentially important role
in epilepsy (31). However, other studies both in humans (14,15,129) and in vitro [For
review see: (130)] suggest that interictal spikes may actually even be protective against
seizures.

To settle these discrepancies would require an animal model of chronic,

neocortical interictal spiking. At the start of this work, no such models existed. Other
models to study epilepsy typically focus on acute, severe seizures and have not been
verified to act through the same molecular pathways as human epilepsy.

Not

surprisingly, antiepileptic drugs developed using these models simply reduce the
likelihood of seizures occurring, but do not correct the underlying brain abnormality that
allows seizures to occur. If a model of chronic interictal spiking could be developed and
is shown to activate the same molecular pathways that are involved in human epilepsy, it
would not only provide new insight into a poorly-understand phenomenon but also allow
for the testing of novel, molecularly-targeted therapeutics.
In this chapter, we develop one such model. Based on the work of Jeffreys on the
tetanus toxin model of chronic epilepsy and the observation by Brener (60) that injection
of tetanus toxin into the rat somatosensory cortex produces predominantly interictal
spikes with minimal seizures, we focused on the use of tetanus toxin in the
somatosensory cortex to create a model of chronic, neocortical interictal spiking. Tetanus
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toxin creates a focus of excitation by preferentially binding to gangliosides of inhibitory
neurons, where it is taken up and prevents vesicle exocytosis through cleavage of
synaptobrevin (VAMP-2) (61-63).

After determining an appropriate dose which

generates frequent interictal spikes without observed seizures (131), we characterize how
this spiking focus develops and progresses over time. We show that a single injection of
tetanus toxin produces a spiking focus which progresses in frequency and amplitude over
time and that spikes progressively cluster together, weeks after the tetanus toxin is
cleared from the brain. We show that interictal spiking alone is enough to induce the
activity-dependent gene expression changes seen in our human patients in some rats, and
that these genes are activated in the same cortical layers as in human epilepsy. Finally,
after our work in human patients implicated the MAPK-CREB pathway as central to
epilepsy, we demonstrate that a selective inhibitor of the activation of MAPK can prevent
the development of a spiking focus.

METHODS

Surgery and electrode implantation
All studies were carried out with approval by Wayne State’s Animal Investigation
Committee (AIC protocol A01-09-06). Male Sprague-Dawley rats at four months old
were kept on a 12-h light/dark cycle with free access to food and water. Rats were
implanted with recording electrodes and tetanus toxin was stereotactically injected as
previously described with modifications (59,60). Rats were anesthetized with
pentobarbital, placed in a stereotactic frame and holes were drilled in the skull over each
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hemisphere at AP +4mm, -1mm and -6mm, L3.5mm relative to the bregma (Figure 4). A
seventh hole was drilled at the midline over the nasal sinus. Tetanus toxin (Sigma,
catalog# T3194) was reconstituted with sterile water to 100 ng/μL in 0.01M sodium
phosphate and injected into the left somatosensory cortex (AP-1mm, L 3.5mm, as
measured from bregma) at a depth of 1.5 mm over four minutes. As tetanus toxin lots
varied in potency, the dose injected was modified to produce the same amount of spiking
when a new lot was purchased. The rats used in the in situ hybridization time course
(described below) received 65 ng, while all others in this study received 100 ng. The
needle was left in place for 10 minutes to allow diffusion and binding of the toxin. Small
screws were placed in each drilled hole and wired to a plastic connector to serve as
electrodes, with the nasal sinus screw used as a common reference. For the in situ
hybridization time course, parts were obtained from Plastics1 (Parts MS363 and E363),
while for all other rats, the screws were from Small Parts, Inc (TX2-4-1C) and the
connector from Molex (Part#0430450829). Connector types did not have any discernable
effect on any measurements made in this study. The apparatus was secured with dental
cement and the skin closed. Recordings were made using a 32-channel Stellate Harmonie
system recording at 200Hz for one-hour periods at the same time of day over the course
of three weeks.

Evolution of the interictal spiking focus over time
To study the initiation and development of a chronic, neocortical interictal spiking
focus over time, an initial group of tetanus-injected (n=7) and vehicle-injected (n=5)
animals were followed over the course of three weeks. The four 3-week time point rats
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from the in situ hybridization time course described below were added to this initial
dataset to give a total of 11 tetanus-injected rats for this study.

Recordings were

reviewed in a referential montage (recording electrodes subtracted from the nasal sinus
reference) and the location of spikes was marked manually by a single, blinded reviewer.
Quantitative parameters about the spikes, including frequency, duration, amplitude, slope
and field distribution on each recorded day were calculated for these marked locations
using custom Matlab scripts (MathWorks, R2008b, Natick, MA). For the measurement
of spike clustering, spikes occurring within 500 ms of each other were considered
members of the same spike cluster. Three-dimensional plots of data on rat brains were
generated using software developed for us by the Graphics and Imaging Lab (Dr. Jing
Hua and Darshan Pai) of Wayne State University’s Computer Science Department.

Activity dependent gene expression by in situ hybridization
Previous studies of human neocortex in our lab (10,31) suggested that interictal
spiking may drive activity-dependent gene expression through CREB phosphorylation in
human epilepsy.

To determine whether interictal spiking alone can drive activity-

dependent gene expression, groups of rats were sacrificed at multiple time points after
initiation of a spiking focus and subsequently examined via in situ hybridization. Four
rats per time point were sacrificed at one week, two weeks and three weeks after tetanus
injection, with an additional three surgery-naïve rats used as controls. Each rat was
sacrificed via a CO2 chamber and its brain was immediately dissected and fixed in 4%
paraformaldehyde/PBS at 4ºC. After subsequent equilibration in 30% sucrose in PBS,
brains were cryosectioned at 20 μm. In situ hybridizations were performed using
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S-
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labeled RNA probes as previously described (11). Full-length human cDNA clones
(NARP: 5198692; BDNF: 5193877; GAPDH: 95132246CA2) or expressed sequence
tags (EGR1: 6188360, truncated 3’ untranslated region) (Open Biosystems) were
sequence verified and confirmed to share >=87% identity with the rat sequence. Despite
the availability of FANTOM clones (132), these clones were chosen because they had
previously been used in our human neocortical sections and contained high sequence
identity so that rat neocortical in situ hybridizations could be directly compared to the
previous human ones. Additionally, these clones had been tested previously in our rat
sections and showed the expected distributions of signal, while antisense controls showed
no signal. Immunohistochemical staining for phosphorylated CREB was also performed
on sections adjacent to those used for in situ hybridization.
Prevention of interictal spiking focus development using a MAPK pathway inhibitor
Because the MAPK pathway was the pathway most strongly implicated in human
epilepsy (10,11), we asked whether inhibition of this pathway could prevent the
development of a spiking focus in the tetanus toxin model. The compound SL327 was
chosen for this study because it selectively inhibits a member of the MAPK pathway,
mitogen-activated protein kinase kinase (MEK), in organotypic slice cultures, blocks
ERK1/2 phosphorylation in a dose-dependent fashion and crosses the blood-brain barrier
(133,134). SL327 was obtained from Sigma-Aldrich (St. Louis, MO, catalog# S4069).
First, a dosing regimen had to be determined because this compound had never been used
in a chronic manner in any reported literature. SL327 was dissolved in DMSO at a
concentration of 25 mg/mL and injected intraperitoneally into three rats at a dose of 50
mg/kg. To determine plasma half-life and speed of brain penetration, the three rats were
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sacrificed at 1 hour, 4 hours, and 24 hours after injection and their brains were removed
and frozen at -80ºC. Prior to sacrifice, blood samples were obtained via orbital bleeding
at 15 minutes, 30 minutes, 1 hour, 4 hours 8 hours and 24 hours after injection up until
the sacrifice time of each rat. Blood samples were centrifuged at 800 g for 10 minutes
and then frozen at -80ºC until the time of analysis. Drug concentrations in all samples
were determined using high-performance liquid chromatography with tandem mass
spectrometric detection (HPLC-MS/MS) by our collaborator in Pharmacology, Dr. Jing
Li.

Pharmacokinetic parameters such as terminal elimination half-life, volume of

distribution and clearance were estimated using non-compartmental analysis in the
software WinNonlin Professional 5.2 (Pharsight Corp., Cary, NC).
Once a dosing regimen that would maintain drug levels similar to those reported
to be effective acutely had been determined, SL327 was tested for its ability to prevent
CREB phosphorylation in vivo in our tetanus toxin model. Four rats were given i.p.
injections of 25 mg/kg SL327 dissolved at 25 mg/kg in DMSO twice daily for a week
following tetanus injection, while another group of three rats were given only an
equivalent volume of DMSO. After one week, rats were sacrificed and their brains
examined for CREB phosphorylation by immunohistochemical staining.
Once the ability of SL327 to prevent CREB phosphorylation in the tetanus toxin
model was established, its ability to prevent the development of an interictal spiking
focus was tested.

Three rats were injected with tetanus toxin and electrodes were

implanted in the skull, as part of the usual protocol. For the week following surgery
though, they were each treated with SL327 and monitored for interictal discharges for a
total of four weeks.
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RESULTS

Spikes increase in frequency, amplitude and slope over time
The injection of tetanus toxin into the rat somatosensory cortex successfully
generates ‘interictal’ discharges with no initiating seizure. Spikes can be detected on
EEG starting around days three to five after injection, and then increase in frequency with
time (Figure 5A). Vehicle animals show significantly less spiking at the first week
(p=0.029, one-tailed t-test, Bonferroni correction; 79.1±18.1 and 9.4±2.9 spikes/ hour, ±
sem), which persists at two weeks (p=0.020, one-tailed t-test, Bonferroni correction;
101.3±19.5 and 9.5±2.9 spikes/ hour, ± sem) and three weeks (p=0.040, one-tailed t-test,
Bonferroni correction; 178.33±45.3 and 8.6±4.2 spikes/hour±sem). Spike amplitude
increases initially, but then appears to plateau by 10 days (Figure 5B; Best fit model:
y=a*xb+c; R2=0.667).

Spike slope increases progressively with time (Figure 5C;

R2=0.530; Linear regression slope=0.307μV/day, p=0.0004), while duration does not
appear to change (Figure 5D; R2=0.148; Linear regression slope=-0.299ms/day,
p=0.104).

Spike clustering
Spikes were observed to progressively cluster together over time (Figure 6).
While spikes initially appeared as individual, isolated discharges, ‘doublets’ often
appeared by a week after injection and became progressively more common. As time
went on, longer runs appeared and became more common, so that by three weeks over
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30% of the spikes in a recording occurred clustered with other spikes (R2=0.492; Linear
regression slope=0.75%/day, p=0.0025). A single animal with frequent repetitive bursts
was also observed to develop a focal seizure from this focus, but the exact relationship
between spike clustering and seizures cannot be drawn from this data, given that long
term recordings were not part of this project.

Spike field expansion
The placement of six epidural recording electrodes allowed us to not only detect
interictal discharges, but to track their electrical field and spread over time (Figure 7).
Rats varied in their patterns of field expansion so that while most were restricted to the
injection site and left anterior electrode (Figure 7A,B), a small number of rats developed
a spiking focus restricted to the right hemisphere, contralateral to the injection site
(Figure 7C,D).

This finding is consistent with other studies using tetanus toxin in

hippocampi, where injection in one hemisphere sometimes leads to epileptic activity
initiated in the opposite hemisphere (60,135). Combining all surveyed rats together,
however, shows that the most common pattern of expansion was to begin with small
spikes at the injection site, spread to involve the left anterior electrode, and then
eventually involve the right middle electrode (Figure 7E). Interestingly, spikes never
spread posteriorly from the injection site, suggesting that the pattern of interictal spike
spread is closely related to normal anatomic barriers that separate cortical areas of
different function.

Activity-dependent gene expression
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Previous results from our laboratory showed that activity-dependent gene
expression changes correlate with interictal spiking. Further, these expression changes
could be localized to specific lamina of the neocortex, predominantly layers II and III.
To ask whether interictal spiking alone could induce changes in activity dependent gene
expression, we performed in situ hybridizations on multiple animals sacrificed at one,
two and three weeks after tetanus toxin injection. The genes examined in this study were
chosen because they had all been previously shown as robustly differentially expressed in
human epilepsy and represented several different functional categories. Egr1 and Bdnf
are immediate early genes (136-141) and Narp (Nptx2) clusters AMPA-type glutamate
receptors at excitatory synapses (142,143).
Three of the four animals sacrificed after one week of spiking showed a small
region of suppression at the injection site, with one also showing a focus of strong gene
induction at the center (Figure 8). This focus showed Egr1, Narp, and Bdnf expression in
exactly the same area on adjacent sections. This pattern was virtually identical to the
pattern of Egr1 protein distribution in another study using tetanus toxin in the motor
cortex (144). By two weeks, rats that were sacrificed during a time of recent increases in
spike frequency and amplitude showed increased gene expression in the left, spiking
hemisphere than the right, non-spiking hemisphere. By three weeks, however, most rats
had stabilized in spike frequency and/or amplitude and no longer showed lateralized
differences in gene expression, even when spike field was well-restricted to one
hemisphere. Normal, surgery-naïve rats and 0.01M vehicle-injected rats showed even
hemispheric gene expression throughout, and antisense probes showed no signal.
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In rats with lateralized gene expression changes, these changes were consistently
in layers II/III of the neocortex, just as we previously found in human epileptic tissue
(10,11). Egr1 generally filled layers II and III, while Narp and Bdnf were restricted to
thin bands in the superficial part of layer II. Again, these results parallel our previous
findings in human neocortex. Despite the varying patterns of expression in the rats
surveyed, all rats were internally consistent in that all the genes detected were
upregulated in the same areas as the others on adjacent sections.

MAPK pathway inhibition prevents the development of a spiking focus
MAPK-CREB signaling was by far the pathway most implicated in the human
epileptic transcriptome (10,11), so it seemed a logical target for therapeutic intervention
in our animal model. In this experiment, we therefore determined a dosing regimen for
the MAPK pathway inhibitor SL327, verified that it was able to prevent CREB
phosphorylation after one week of treatment, and then tested its ability to prevent an
interictal spiking focus from developing. One week after the induction of a spiking
focus, CREB is usually phosphorylated in the left, spiking hemisphere relative to the
right, non-spiking one (Figure 9A; n=5/7 rats). Using plasma and brain concentrations of
SL327 over time (Figure 9B), Dr. Jing Li calculated the half-life to be 6.8 hours and
recommended dosing the rats twice daily with 25 mg/kg. Rats treated with this dose for
one week following tetanus toxin injection showed markedly reduced CREB
phosphorylation relative to DMSO-injected controls (Figure 9C). Treatment of rats with
SL327 during the first week after tetanus injection significantly reduced spiking rate
(Figure 9D) by the first week (p=0.005, one-tailed t-test, Bonferroni correction; 79.1 ±
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18.2 and 7.0 ± 3.6 spikes/ hour, ± sem) that persisted at 2 weeks (p=0.044, one-tailed ttest, Bonferroni correction; 100.5 ± 27.3 and 18.0 ± 9.0 spikes/ hour, ± sem) and 3 weeks
(p=0.013, one-tailed t-test, Bonferroni correction; 178.3 ± 45.3 and 30.7 ± 7.6 spikes/
hour, ± sem), suggesting that MAPK is necessary for the development of interictal
discharges. SL327 treated animals did not significantly differ from vehicle animals at
any of these time points.

DISCUSSION

Interictal spikes may be a precursor for epilepsy and seizures
In this chapter, we characterized a rat model of chronic, neocortical interictal
spiking for the first time. The advantages of this model are that it is essentially ‘nonlesional’ in that it does not cause the extensive neuronal loss and gliosis associated with
other models like kainic acid and pilocarpine, and it has a chronic time course that better
parallels the development of human epilepsy (55,56,145,146). Spikes develop after an
initial latent period of several days and then steadily progress in frequency and amplitude
with time, despite tetanus toxin being cleared from the brain by then (147). This implies
that once initiated, a spiking focus is both self-sustaining and expands over time.
Combining this observation with the fact that spikes progressively cluster together with
time raises the intriguing hypothesis that interictal spikes may be an essential precursor to
seizures and an integral part of epileptogenesis (148). This conclusion is supported by a
recent study which shows that both the frequency of interictal spikes and the presence of
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spike clusters predict which animals will develop spontaneous seizures following status
epilepticus in the hippocampal kainic acid model (149).

Layer-specific changes in activity-dependent gene expression are associated with
interictal spiking
Interictal spikes without observed seizures were able to induce activity-dependent
gene expression changes in genes previously confirmed to be upregulated in human
epileptic foci. All changes in gene expression were observed in layers II and III of the
cortex, exactly as we have seen in our previous human studies and in contrast to most
other work in animal models of epilepsy (42). Not all rats showed lateralized gene
expression changes consistent with lateralized spiking, but those that did were the
animals that were increasing in frequency and amplitude at the time of sacrifice, which
may mean that only neurons undergoing active remodeling show detectable differences in
these plasticity-associated genes. No rats showed expressed changes opposite their spike
field and surgery-naïve rats all showed homogenous gene expression. EGR1 (150-152)
and BDNF (153) are regulated by CREB, and while the control of NARP transcription
has not been well studied, its promoter contains a CREB binding site (154,155). While
additional work beyond these initial studies needs to be done, these results so far imply
that this model may be an accurate representation of human epilepsy at the molecular
level and that targeted therapeutics developed in this model are likely to translate well
into human use.
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MAPK-CREB pathway inhibition and drug development
In this study we showed that a MAPK pathway inhibitor can reduce CREB
activation and prevent the development of an interictal spiking focus. These results
support our conclusions from the human epileptic transcriptome, which implicated
MAPK-CREB signaling and present the exciting possibility that entirely novel
therapeutics for epilepsy can be developed. It has been shown that constitutive activation
of ERK, the kinase blocked in this study, causes epilepsy (156) so blocking its activity
may be an effective treatment of epilepsy, or at least prevent its development after injury.
A recent study showed that current antiepileptic drugs block seizures, but do not prevent
spike activity in vitro (157). Since results from our studies suggest a role for interictal
spikes in epilepsy and epileptogenesis, new therapies that target interictal spiking may be
more effective at treating epilepsy than current medications only treat seizures.
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CHAPTER 5
Behavioral consequences of interictal spiking in a rat model
INTRODUCTION
Epilepsy is a disease of recurrent seizures, with most research attention over the
years focusing on the seizures themselves. While seizures are often the major cause of
morbidity for patients, patients with epilepsy also suffer from a wide range of comorbid
brain disorders, not always linked directly to seizures.

For example, estimates of

attention-deficit hyperactivity disorder (ADHD) in children with epilepsy range from 2040%, while the incidence in the general population is only 3-7% (66-72). Patients with
epilepsy are also more likely to have depression (68,73-78), anxiety disorders
(68,73,75,77-79), and other psychiatric conditions (68,71,78-82). Given that seizures
occur infrequently and that most of a patient’s life is spent in the interictal state between
seizures, it is conceivable that these comorbid conditions are better related to a process
going on between seizures, rather than the seizures themselves. Interictal spikes would
be a prime candidate for this abnormal process.
Outside of the increased comorbidities in patients with epilepsy, interictal spikes
have also been associated with most of these conditions in the absence of an epilepsy
diagnosis as well. Interictal discharges have been most strongly linked to children with
ADHD, even in the absence of epilepsy (158-163). Several other studies have linked
epileptiform discharges to a variety of other psychiatric ailments, including depression,
anxiety disorders, and obsessive-compulsive disorder (84-86). With all the evidence
linking interictal discharges to behavioral and psychiatric disorders, an animal model of
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chronic interictal spiking without seizures may provide insights into these disorders and
allow them to be studied in vivo in a way not previously possible.
In Chapter 4 we showed that the tetanus toxin model of interictal spiking can
reliably produce spikes without seizures. Additionally, it shows induction of several
activity-dependent genes in a similar pattern found in human epilepsy, suggesting that
this model may also be a good model to explore comorbidities.

In this chapter we

demonstrate that our animal model of interictal spiking leads to specific behavioral
abnormalities. We also demonstrate for the first time that interictal spiking can be
induced by environmental stimuli in animals with an epileptic focus. We show that
spiking rats are more active, that the level of their activity correlates with their level of
spiking on a day-by-day basis, and that lateralized spikes cause lateralized movements.
Suppression of interictal spiking with a MEK inhibitor normalizes these behaviors.
These studies not only raise important questions on the significance of interictal spiking
in patients with epilepsy, but also provide a novel animal model to develop novel
pharmacological treatments for interictal spiking that could also have important effects
on behavior.

METHODS

Open-field activity measurements
Rats underwent the same surgical procedure and tetanus toxin injection to initiate
neocortical interictal spiking as described previously in Chapter 4. Four tetanus-injected
and four sham-operated (electrodes implanted, but no injection into brain) animals were
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followed over time to measure the effect of progressive interictal spiking on open-field
activity. Immediately after EEG was recorded for one hour, rats were placed in an openfield activity chamber (ENV-515, MedAssociates, Inc., St. Albans, Vermont) for an hour,
which uses an array of infrared beams to track movement.

The included Activity

Monitor software was used to calculate total ambulatory distance over each one-hour
recording period.
To examine the effect of focal interictal spiking on behavior in more detail, a
group of seven tetanus-injected animals were placed in the open-field activity chamber
immediately following an EEG recording session. The ratio of the number of spikes
from the left hemisphere to the number of spikes in the right hemisphere as well as total
spike power (frequency * amplitude) were compared to the ambulatory distance, resting
time, and the ratio of counter-clockwise to clockwise rotations, as calculated by the
Activity Monitor software. For these comparisons, the numbers within each rat were
converted to Z-scores so that data from multiple rats could be combined together for an
overall correlation.

Auditory evoked interictal spikes
To measure the effect of a startle evoked by an auditory stimulus, a total of 11
spiking rats and five vehicle rats were monitored over time for their response on EEG to a
repeated stimulus. To induce spikes in a reproducible manner, a digital audio recording
of a single clap was made. While EEG was being recorded, this sound was played in the
recording chamber three times at intervals of 10 minutes apart, followed 10 minutes later
by a train of three repetitions, each one second apart (Figure 11A). Responses were
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marked on the EEG files and spike amplitude in each channel was calculated using a
Matlab script. The response to the three claps spaced 10 minutes apart were averaged
together for each day as a measure of response magnitude at each time point, while the
train of spikes was considered separately to measure extinguishment of the response.

Effect of suppressing interictal spikes on behavior
From the results in Chapter 4 that showed that SL327, a selective MEK inhibitor,
can prevent the development of a spiking focus, we hypothesized that this suppression
could normalize behavior in tetanus-injected rats. Five tetanus-injected rats, four vehicleinjected rats, and three rats who received tetanus toxin followed by SL327 for one week
after surgery were followed over time to measure the effect of progressive interictal
spiking on open-field activity. While EEG was being recorded for one hour, rats were
placed in the open-field activity chamber and monitored for ambulation distance over
time.

RESULTS

Interictal spiking increases rat motile behavior
As a first step, we determined the ambulatory behavior of rats with progressive
increases in interictal spiking after tetanus toxin injection into somatosensory cortex.
Infrared measurements of ambulatory mobility performed daily showed that interictal
spiking is associated with a significant increase in rat ambulation, leading to what could
be termed a ‘hyperactive’ rat (Figure 10A). The average ambulatory distance of spiking
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rats was greater than that of sham controls at all time points measured, and showed the
most divergence toward the end of the three week period when tetanus-injected rats were
at their maximal spiking (1 week: p=0.082, 7946.5±851.0cm versus 5605.7±759.4cm; 2
weeks: p=0.079, 7808.2±1046.1cm versus 5501.3±571.3cm; 3 weeks: p=0.0005,
8610.0±733.8cm versus 4668.0±504.5cm; distance±SEM, all p values after Bonferroni
correction).
Next, we looked in more detail at the relationship between interictal spiking and
movement parameters. For seven rats followed either for two weeks (n=3) or three
weeks (n=4), spiking was measured for one hour immediately prior to placing the rat in
the open field activity chamber for one hour. The ratio between the number of spikes
originating in the left hemisphere versus the number originating in the right hemisphere
correlated significantly with the ratio between the number of counter-clockwise and
clockwise rotations the rats made (Figure 10B;

R=0.396, p=0.013 Bonferroni

correction). This result means that more interictal spikes on a rat’s left caused it to rotate
more frequently counter-clockwise to its own left side, while right-sided spikes are
associated with clockwise rotations.

Total spike power correlated positively with

ambulatory distance (R=0.350, p=0.039 Bonferroni correction) and negatively with
resting time (R=-0.410, p=0.008 Bonferroni correction).

Therefore, not only are

interictally-spiking rats hyperactive as a group relative to control animals, but within just
spiking rats the level of their activity varies with the level of spiking on that day.

Startle-induced spikes occur in same field as spontaneous spikes
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A startling auditory stimulus, such as a clap in this case, consistently evokes an
interictal spike in rats that are already spiking. The field of the spike induced is always
the same as each rat’s individual spontaneous spike field. Figure 11B shows an example
rat that has spontaneous spikes originating predominantly under the middle, left electrode
(L2) with a small contribution in the contralateral electrode (R2). When this rat is
startled, the induced spike occurs with the exact same distribution, although with a
slightly higher amplitude. As an illustration of a rat with an entirely opposite field,
Figure 11C shows a rat which has spontaneous spikes originating from the right, middle
electrode (R2). Predictably, the spikes induced by an auditory stimulus in this rat are
restricted to the same electrode, but again at slightly higher amplitude than the average
spontaneous spike.

Every tetanus-injected rat showed this correspondence between

spontaneous and induced spike fields, while vehicle rats did not have a response on EEG
when startled.
Not only do induced spikes have an identical field as each rat’s spontaneous
spikes, but the response changes with time as the spiking focus changes. As the average
amplitude of a rat’s spontaneous spikes increases over time, so too does the average
amplitude of the induced spikes. Figure 11D shows the correlation between average
spontaneous and induced spike amplitudes over time, measured at the channel of
maximum amplitude in each rat and normalizing amplitudes in each rat so that the
maximum value is 100% (R=0.535, p=1.42x10-9).
The EEG response of induced spikes seems to depend on the rat being genuinely
startled. When the recorded claps are spaced only one second apart instead of 10 minutes
apart, the response extinguishes rapidly (Figure 11E).

The first response was
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significantly larger than the response to the second stimulus (650.2±40.0μV versus
273.1±43.4μV; p=8.1x10-9, Bonferroni correction; amplitude±SEM) and the response to
the third stimulus (650.2±40.0μV versus 156.2±28.7μV; p=1.1x10-21, Bonferroni
correction; amplitude±SEM). The second and third responses did not significantly differ
after correcting for multiple comparisons (273.1±43.4μV versus 156.2±28.7μV; p=0.079,
Bonferroni correction; amplitude±SEM). Anecdotally, a sudden, unexpected touch on
the rat’s back can also induce an EEG spike when the rat is startled. While this was not
possible to repeat in a consistent enough manner to quantify, it suggests that the response
observed in this study is not a unique feature of the auditory system, but more likely
represents a startled response to any stimulus.

Suppression of interictal spiking normalizes behavior
To show that interictal spiking truly alters rat behavior, tetanus-injected rats were
compared to rats who received both tetanus toxin and a selective MEK inhibitor that
prevents the development of a spiking focus. Pooling ambulation data for weeks one,
two and three after surgery shows that while tetanus-injected rats increase in ambulatory
distance over time, rats treated with the MEK inhibitor SL327 for one week after tetanus
injection (same as those described in Chapter 4) remain about the same (Figure 12). In
contrast to the ambulatory measurements described previously in this chapter, these rats
were monitored for ambulation while simultaneously having EEG recorded. Therefore,
the presence of the recording tether reduced overall movement distance, accounting for
the vastly different scaled between Figure 10A and Figure 12. The two groups do not
differ in the first week (p=0.645, t-test, Bonferroni correction; 1144.5±197.3cm and
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711.8±293.8cm), but by the second week the spiking animals were moving more than the
SL327 treated ones (p=0.025, t-test, Bonferroni correction; 1205.4±127.9cm and
627.7±150.5cm). By the third week, the two groups had diverged widely (p=0.012, t-test,
Bonferroni correction; 1692.6±193.3cm and 759.0±223.1cm). Vehicle animals showed
no increase over time and ambulated almost exactly as much as the SL327-treated
animals (729.4±93.2cm).

DISCUSSION

Interictal spiking causes hyperactive movement
In this chapter, we showed that spiking rats are hyperactive relative to shamoperated control rats.

This result is especially interesting in the context of reports

showing that ADHD is frequently associated with epilepsy and that interictal discharges
are more common in children with ADHD than normal children, even in the absence of
epilepsy. More spiking was also associated with more ambulation and less resting time
on a day-by-day basis. Again, these results strengthen the conclusion that interictal
spikes directly cause the observed changes in behavior. Further, location of the interictal
spiking focus caused asymmetric ambulation in spiking rats. The ratio between left and
right hemispheric spikes was correlated with the ratio between counter-clockwise and
clockwise rotations, meaning that as the number of spikes originating from the left
hemisphere increased, so too did the number of counter-clockwise rotations.

Since

tetanus toxin was injected into the left somatosensory cortex, it is possible that interictal
spikes in this region caused the rat to feel a negative sensation on the right side of its
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body, and then turn away from it. Therefore, not only does the presence of interictal
spikes affect behavior, but the type of behavior observed appears to depend on their
location. These are the first in vivo results showing an effect of neocortical interictal
spiking on behavior, and together suggest that the tetanus toxin model of neocortical
interictal spikes may be able to offer insights into a range of psychiatric disorders where
interictal spikes have been observed.

Environment can influence interictal spiking
Next, we demonstrated that interictal spikes can be induced in spontaneouslyspiking rats by a startling sound. Further, these induced spikes always occur in the same
field distribution as each rat’s spontaneous spikes, implying that the same population of
hypersynchronized neurons is likely being activated in both cases and that these neurons
are more easily brought to threshold than normal neurons. This is perhaps the first
observation that a common environmental stimulus such as sound can alter interictal
activity in vivo.

Suppression of interictal spiking normalizes behavior
Finally and perhaps most importantly, we showed that treatment with a MEK
inhibitor during the first week following tetanus injection prevented the hyperactivity
seen in the spiking rats. While it is true that the drug itself could reduce rat movement by
negatively impacting their health, this effect would be expected to cease once treatment
stopped in the first week. By the third week any residual drug effects are gone and rats
have returned to their normal health state, yet SL327-treated rats show no increase in
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ambulation at this time. Instead, their total ambulation remained constant throughout the
monitoring period and was essentially identical to that of the non-spiking vehicle rats.
Together, these results imply that interictal spiking itself is directly responsible for the
increased activity and that this effect can be mitigated with a selective molecular
inhibitor. While this study has only explored the prevention of a spiking focus with a
MAPK pathway inhibitor, MAPK inhibition should be explored as an entirely new
therapeutic strategy for a variety of psychiatric disorders with epileptiform abnormalities.
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Chapter 6
Discussion

Quantitation of interictal spikes to improve surgical outcome and advance research
In Chapter 2 we demonstrated that professional electroencephalography (ECoG)
reviewers varied widely in their detections of interictal spikes. Such variation could lead
to subjective clinical decisions and make it difficult to compare results between research
studies on interictal spikes. This may explain why there have been mixed results in the
use of interictal spikes to identify the seizure onset zone and improve surgical outcome
(16-23). Due to the tremendous variation in spiking rates over time within patients(17)
and the frequency of spikes on ECoG, manual marking of interictal spikes is simply not
feasible as regular, reliable method of quantifying ECoG. While many other algorithms
for spike detection have been published (for review see: (122)), only a few have been
verified on intracranial recordings (29,121,123,124) and these have either only examined
single channels or verified spikes already detected by humans. Here, we showed that our
method can be run on full ECoG recordings and still preserve differences in activity
between channels. Additional benefits to this method are that it requires no changing of
parameters for each patient, runs very quickly, and is fairly simple to implement.
We subsequently used this spike detection algorithm to see if other parameters
besides spike frequency could be used to identify regions of seizure onset.

We

determined that brain areas which either generate or participate in seizures cannot be
distinguished from each other based on these interictal spike parameters, but that these
epileptic regions differ from control regions. In this group of non-lesional patients, the
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parameters examined did not significantly improve upon spike frequency for the
identification of seizure onset zones, but several characteristics of spikes did perform
equally well. In the future, it might be possible to show that different parameters do a
better job with different patients. For example, spike morphology might be affected by
disease duration, initiating etiology, antiepileptic medications, or functional area of the
brain in which it occurs. With a larger sample of patients, it may be possible to stratify
patients into groups and find which parameters of spike morphology best fit each
subpopulation.
The use of ECoG in tumor surgery patients provided new and interesting results,
since this method is rarely used in tumor surgeries. Here we found that the spiking
parameters which best identify seizure onset zones in lesional patients are different than
those found in non-lesional patients. In this group of tumor patients, frequency was not
the best measure of seizure onset areas; duration of the second halfwave was a much
better marker. More surprisingly, we found that seizure onset areas regularly lie outside
of the immediate tumor area, and that increasing spike frequency was actually correlated
with increasing distance away from the tumor. These results suggest that the use of
ECoG in tumor patients with comorbid epilepsy may give valuable additional
information to the surgeon. An expanded group of patients followed after surgery for
post-operative outcomes will eventually answer whether there is a true clinical advantage
to using ECoG data in these tumor resections and for which types of patients it is most
helpful.
One problem in the world of spike detection is that techniques are developed and
papers are published, but then no one but the authors use the algorithm that they
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developed. Widespread adoption of this algorithm could be facilitated by integrating it
into a broader set of tools. Now that we have developed and verified an automated
method of spike detection, a whole host of research questions can be asked about the
relationship between interictal spikes and epilepsy which would have been impossible to
do in an objective, efficient manner previously. The next steps in development could be
to integrate it into ECoG recording software so that detections can be made in real time,
and then include new quantitation and visualization tools. We are currently working with
Dr. Jing Hua in the Computer Science department to be able to display spike detection
results on a three-dimensional image of a patient’s brain in real time. This would allow
clinicians and researchers to visualize how groups of electrodes are linked to each other,
whether spikes in one area lead and perhaps drive spikes in another area, and determine
how spiking patterns change with time or patient activity.

Interictal spikes in epileptogenesis
In Chapter 3, we described the development and characterization of an animal
model of chronic, neocortical interictal spiking. In this model, a single injection of
tetanus toxin is followed by a latent period of several days before spikes are first
detected.

Spikes then increase in frequency, amplitude, electrode involvement and

clustering with time, even after the initial insult (tetanus toxin) is gone. This pattern
mirrors the development of acquired epilepsy in humans, although on a shorter time
scale. The latent period before seizure development in humans can range from months to
years after the initial insult (1,55,56). The absence of an initiating seizure in this model
allows the effects of in vivo interictal spiking to be isolated, and the increase with time

56

shows that they are not benign.

In fact, the progressive clustering of spikes may

represent the process that takes place during the latent period before clinical seizures in
human epilepsy. More frequent and longer clusters of spikes indicated that the brain is
changing with time in a way that allows faster recovery from a massive depolarization
and the ability to depolarize again more quickly. As a focal seizure is often arbitrarily
defined as lasting for 10 seconds (164), a sufficiently long train of interictal spikes would
be indistinguishable from a focal seizure, and likely represents a transition from single
interictal spikes to electrographic seizures. Recent work in the kainic acid model of
hippocampal epilepsy supports the role of interictal spikes in epileptogenesis. White, et.
al. demonstrated that after kainic acid-induced status epilepticus, interictal spikes appear
before spontaneous seizures (149). Further, increasing spike frequency and increasing
spike clustering were predictive of which animals would develop convulsive seizures in
the future. Our work adds to this study and shows a similar pattern of spike progression,
but without any initiating seizure and in an entirely different animal model.
Data from our laboratory’s work in human epilepsy showed CREB
phosphorylation and activity-dependent gene expression predominantly in layers II/III of
the neocortex (10,11).

Initial work in the tetanus toxin model of neocortical interictal

spiking agrees with these findings, which both supports the validity of our human
findings, as well as the use of the tetanus toxin model as a molecularly-accurate model. It
is important to note, however, that only 57% of canonical cyclic AMP response elements
(CREs; sequence TGACGTCA) are conserved between human and rat, so the two species
may exhibit somewhat different transcriptional profiles (165). Further characterization
therefore needs to be done in order to be certain that this animal model sufficiently
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replicates the human disease. The significance of layers II and III is that these are the
layers primarily responsible for lateral, associative communication with other cells of the
cortex (166). It is conceivable therefore that that the spiking focus expands through these
lateral connections. Under this model, an initially small focus of hyperexcitability is
created by some initial lesion (human patients) or tetanus toxin’s cleavage of
synaptobrevin (167) (rat model). The affected neurons would signal excessively on the
‘neighbors’ they are connected to, which would induce activity-dependent pathways in
these neurons and cause them to become synchronized with the original group (see
Figure 13 for schematic of MAPK pathway’s proposed role in this model). Continued
spiking could expand the focus in a similar matter until a large population of neurons in
the superficial cortical layers has become excessively synchronized, and spikes can be
detected as field potentials. Further alterations in synaptic efficacy and recovery times
could lead to the generation of clustered spikes and eventually seizures.
Further studies would be required to prove this hypothesis. First, the results from
in situ hybridizations presented in Chapter 3 showed changes in gene expression only in a
subset of animals which were undergoing increases in spike frequency and amplitude at
the time of sacrifice, while most animals showed no lateralized changes, even if spikes
were frequent and well-restricted to one hemisphere. These data lead us to the hypothesis
that activity-dependent gene expression in this model can only be detected while neurons
are actively undergoing synaptic plasticity and long-term potentiation. To confirm this
hypothesis, instead of deciding to sacrifice rats at an array of time points as was done
here, rats should be continually monitored for spiking parameters and sacrificed during
periods of rapid increase. The initial work on the tetanus toxin model of neocortical
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interictal spiking presented here demonstrates that individual rats vary widely in the rate
of progression of their spiking focus, so that it will be more logical to group rats by
observed spiking parameters than to attempt to group them by arbitrary time points. This
method may more consistently reveal the link between activity-dependent gene
expression and interictal spikes in this model.
Finally, one of the most important studies to next be carried out in this model will
be to examine the progression from interictal spikes to seizures. We recently installed
equipment for continuous EEG monitoring of rats, so we can now follow rats constantly
and determine when seizures first develop in this model. This will hopefully allow us to
determine which variables, such as spike clustering, are most important for the
progression from interictal spikes to seizures. We would also be able to sacrifice rats that
have just developed seizures and ask how they differ at a molecular level from rats who
do not have seizures. In fact, it may be prudent to categorize rats into non-spiking,
individual spiking, clustered spiking, and seizures to see if different signaling and
transcriptional profiles are activated in each. For example, blocking Phospholipase C in a
hippocampal slice culture model is able to prevent the initiation of interictal spiking, but
not the continuation of spiking once it has been established (168). Protein Kinase C
(PKC) activation, on the other hand, is able to convert single interictal discharges to
clustered bursts of spikes in guinea pig hippocampal slices (169).

Behavioral changes of the interictal state
In Chapter 5, we showed that interictally-spiking rats exhibit several behavioral
changes. These observations are important in light of the numerous conditions comorbid
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with epilepsy (66-82), and the observations of spikes in a broad array of psychiatric
disorders as described previously (158-163). We first observed that interictal spikes
could be induced by a simple, external stimulus such as a clap. The field of the induced
spike was identical to each rat’s spontaneous spikes and its amplitude varied with
spontaneous spikes amplitude as well, strongly suggesting that the same group of neurons
is involved in both cases. Given the old adage among epileptologists that “seizures beget
seizures” (170,171), it may also be true that spikes beget spikes, in which case this study
could have implications for how epileptic patients should be treated.

To test this

hypothesis, groups of rats could be set up in parallel, where one group is subjected to
random, startling sounds while the other group is not, and spontaneous spike frequency
could be monitored over time. Given the innate variability in this model, however, a
large number of rats would need to be used in order to detect differences in spiking with
sufficient power.
The next major result is that rats with interictal spiking are hyperactive relative to
non-spiking controls. This is a very significant observation, as interictal spikes are still
often considered symptomatically benign, despite the associative studies in psychiatric
literature. Neocortical interictal spikes without seizures have never been previously
shown to have behavioral effects in an animal model. The only other studies showing an
effect of interictal spikes on behavior or cognition in animal models were just published
this year. One that showed hippocampal spikes impaired memory retrieval and response
time to tasks (172) and another showed that hippocampal spikes during neonatal
development impaired reference memory and long-term potentiation in these rats as
adults (173). Finally, we observed that spiking rats turned counterclockwise more often
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than clockwise in proportion to the number of spikes originating from the left versus right
hemispheres on the day of recording. Therefore, the location of the interictal spike
actually influences the behavior displayed.
Taken together, these results argue for a potential role of interictal spikes in the
comorbidities of epilepsy or psychiatric disorders. It may therefore be beneficial to treat
not only seizures, but also interictal spikes in epilepsy patients experiencing comorbid
conditions, and to look for the presence of interictal spiking more often in psychiatric
patients. The tetanus toxin model described here provides a new animal model in which
hypotheses and eventually treatments for these human ailments can be tested.

MAPK pathway inhibition as a new therapeutic for epilepsy
The role of the MAPK pathway in epilepsy, especially ERK, has been implicated
by both human (174,175) and animal studies (176-180). In fact, conditional expression
of a constitutively active form of ERK in rats was shown to cause epilepsy,
demonstrating that ERK activation alone is sufficient to cause the disease, at least in an
animal model (156).

Transcriptional analysis by microarrays in our laboratory has

provided the strongest evidence to date that MAPK activation is central to human
epilepsy (10,11). Components of the MAPK pathway were greatly enriched in the
epileptic transcriptome, and a transcription factor binding site search revealed that the
downstream target, CREB, was enriched over the next factor (serum response factor) by
several orders of magnitude. Therefore, when creating an animal model of epilepsy, we
expected to find evidence of MAPK-CREB activation and then to subsequently test
inhibitors of this pathway as possible treatments. Frustratingly, this was difficult to
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demonstrate consistently in spiking rats either by western blot or immunohistochemistry.
This difficulty may be due to the labile nature of MAPK activation after a stimulus in
neurons (181,182). Regardless, CREB phosphorylation was greater in layers II and III of
the spiking hemisphere in most animals sacrificed one week after tetanus injection,
implying that at least initially it corresponds well to the location of spike activity.
More conclusive, however, was the use of SL327, a compound which selectively
inhibits the phosphorylation of ERK by MEK (133,134). SL327 administered to rats in
the first week following tetanus toxin injection prevented the development of a spiking
focus, providing strong evidence that ERK activation is required for initiation of this
process. This inhibitor was also able to prevent the increase in ambulation associated
with the development of interictal spikes, even weeks after it was discontinued. The next
step will be to see whether treatment with this drug once a spiking focus has already been
established will be able to reduce or abolish interictal spiking, or more importantly, to
prevent the development of seizures. If effective, this would represent an entirely new
avenue of therapy for epilepsy, one which could hopefully correct the underlying brain
abnormality itself, rather than simply reduce the symptom of seizures.

Other therapeutic targets
The MAPK pathway inhibitor used here was chosen because it could be given
simply through an intraperitoneal injection yet still penetrated the brain, and had been
shown to be effective at knocking down ERK and CREB phosphorylation in rat brain in
vivo (133,134). It is certainly not the only option for targeting this pathway though, and
perhaps administration of an inhibitor that does not cross the blood-brain barrier through
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an intracranial cannula would allow higher concentrations to be used without the side
effects of systemic MAPK inhibition. Recent unpublished data from our laboratory
(Bagla S, Brown E, Barkmeier D) suggest that phosphorylated p90-Ribosomal S6 Kinase
is a more reliable marker of epileptic brain areas than either dpERK or pCREB, so it may
actually make a better target for inhibition.
Outside of the MAPK pathway, other signaling cascades may also prove to be
effective therapeutic targets.

Serum Response Factor, for example, plays a role in

activity-dependent plasticity (183-185) and was the second most enriched transcription
factor in our human epileptic transcriptome after CREB. The activation states of other
pathways classically associated with activity-dependent plasticity such as Protein Kinase
A, PKC and Calcium-calmodulin dependent Protein Kinase II (186-189) should be
assessed as well. While they did not appear as top candidates on our human epileptic
microarrays, they may play roles at different stages of the disease, such as the ability of
PKC to convert isolated spikes to spike clusters in vitro (169).

The drawback of all

these inhibitors, however, would be that they are not targeted specifically to the abnormal
areas of brain, but would act generally. As with many medications, the doses could likely
be titrated to find an effective level that causes minimal side effects, but the ideal solution
would be to target drugs directly to the epileptic areas. The ability to target drugs to
neurons based on their activity would solve this problem, but that technology may be
decades away. Instead, a more immediate solution may be to convert spiking neurons
from inducing activity-dependent, long-term potentiation (LTP) to inducing activitydependent, long-term depression (LTD). In normal brain, the balance between LTP and
LTD depends on the discharge timing of the two connected neurons, but application of an
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alpha1-agonist such as methoxamine can force LTD as the only plasticity option (190192). In the presence of methoxamine, any stimulus would induce LTD in an activitydependent manner. It may therefore be possible to use the hyperactive firing of the
epileptic focus to preferentially induce LTD in that neuronal network, with less of an
effect on normal neurons.
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APPENDIX A
TABLES
Table 1 – Reviewer agreement on detecting
individual spikes
Percent of spikes marked by:
>=2 Reviewers All 3 Reviewers
Patient 1
12.7
0.0
Patient 2
30.9
4.3
Patient 3
26.5
4.9
Patient 4
17.8
0.5
Patient 5
39.2
0.7
Patient 6
18.1
1.3
Patient 7
35.7
5.9
Patient 8
16.0
2.9
Patient 9
32.3
7.4
Patient 10
8.1
Mean
23.7%
3.1%

65

Table 2 – Spike detection reviewer variability and algorithm performance
A. HUMAN REVIEWER AGREEMENT WITH OTHER REVIEWERS
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
Patient 9
Patient 10

Mean

Reviewer 1
Sensitivity
Precision
13.1
81.0
55.1
39.9
70.1
29.6
21.2
32.5
19.4
49.5
17.0
33.1
45.7
49.8
33.7
19.2
34.8
61.1
9.7
32.7

32.0

Reviewer 2
Sensitivity
Precision
0.1
100.0
15.3
73.6
19.5
93.9
4.6
58.7
31.9
51.8
7.8
56.6
14.5
75.8
11.5
75.0
17.7
61.5
-

42.8

13.6

71.9

Reviewer 3
Sensitivity
Precision
80.8
13.1
26.5
53.9
13.7
56.1
33.2
26.0
48.8
64.2
35.4
25.5
44.9
53.2
12.6
31.2
45.7
41.2
32.7
9.7

37.4

37.4

B. RANKING OF CHANNEL ACTIVITY
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
Patient 9
Patient 10

Mean

Kendall's
W
0.653
0.795
0.811
0.802
0.882
0.767
0.838
0.622
0.858
0.49

Reviewer 1
0.56
0.705
0.747
0.652
0.796
0.561
0.712
0.416
0.821
0.478

0.752

0.645

Mean Spearman Rank Coefficient*
Reviewer 2
Reviewer 3
Custom script
0.284
0.529
0.85
0.708
0.758
0.493
0.747
0.68
0.551
0.687
0.755
0.949
0.822
0.849
0.901
0.667
0.706
0.834
0.744
0.823
0.915
0.448
0.46
0.583
0.806
0.737
0.697
0.478
0.726

0.657

0.678

0.750

Commercial
0.799
0.585
0.199
0.801
0.817
0.794
0.725
0.352
0.579
0.09

0.574

*For human reviewers, this is the average Spearman’s Rho from comparison to the other two
reviewers. For the computer scripts, it is Spearman’s Rho when compared to the average channel rank
determined by the three human reviewers

C. CUSTOM SCRIPT’S ABILITY TO IDENTIFY SPIKES MARKED BY:
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
Patient 9
Patient 10

Mean

At least 1 Reviewer
Sensitivity
Precision
47.1
58.6
42.4
80.6
8.3
48.2
49.0
60.1
33.8
98.9
20.8
73.4
44.5
86.8
30.3
46.0
67.8
30.5
58.2
19.3

40.2

60.2

At least 2 Reviewers
Sensitivity
Precision
83.1
13.2
65.1
38.3
24.7
38.0
85.8
18.7
51.1
58.5
51.9
33.0
74.5
51.9
71.8
17.4
82.7
12.0
90.7
2.4

68.1

28.3

All 3 Reviewers
Sensitivity
Precision
100.0
0.1
79.0
6.4
46.2
13.1
87.0
0.6
36.0
0.7
40.5
1.8
78.0
9.0
85.7
3.7
83.6
2.8
-

70.7

4.3

D. EXISTING COMMERCIAL SCRIPT’S ABILITY TO IDENTIFY SPIKES MARKED BY:
Patient 1
Patient 2
Patient 3
Patient 4
Patient 5
Patient 6
Patient 7
Patient 8
Patient 9
Patient 10

Mean

At least 1 Reviewer
Sensitivity
Precision
20.8
52.1
45.6
45.3
0.0
0.0
35.3
92.3
29.6
95.9
29.8
82.3
48.6
100.0
23.8
14.4
28.3
26.0
0.1
100.0

26.2

60.8

At least 2 Reviewers
Sensitivity
Precision
55.7
17.8
55.7
17.1
0.0
0.0
65.1
30.3
37.3
47.3
59.7
29.7
60.0
44.1
28.2
2.7
27.8
8.3
0.8
50.0

39.0

24.7

All 3 Reviewers
Sensitivity
Precision
100.0
0.1
39.5
1.7
0.0
0.0
46.3
0.7
18.7
0.4
48.6
1.7
16.6
2.0
14.3
0.2
6.8
0.5
-

32.3

0.8
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Table 3 - Spikes marked only by script, but later verified by
reviewers (Out of 10 per patient)
Reviewer 1
Reviewer 2
Reviewer 3
0
Patient 1
7
1
1
Patient 2
9
4
4
Patient 3
10
7
1
Patient 4
6
0
0
Patient 5
8
5
0
Patient 6
6
0
0
Patient 7
6
2
0
Patient 8
4
0
0
Patient 9
0
0
0
Patient 10
9
4
0.6
Mean
6.5
2.3
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Table 4 – Lesional patient data
Patient Tumor type
1
Oligodendroglioma with astrocytic component - Grade 2
2
Oligoastrocytoma – Grade 3
3
Oligodendroglioma infiltrating
4
Galnglioglioma
5
DNET
Mixed high-grade tumor: Oligoastrocytoma with a nodule of sarcoma –
6
Grade 3
7
Anaplastic mixed glioma - Grade 3
8
Oligoastrtocytoma - Grades 2 and 3 mixed
9
Dermoid cyst
10
Epidermoid
11
Meningioma (transitional type)

Age
54
40
35
22
47

Sex
M
M
M
M
F

42

F

36
44
38
50
40

F
M
F
M
F
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Table 5 – Correlations with interictal spike parameters
Non-lesional
Lesional
Seizure Category
Seizure Category
Distance from tumor
0.111
0.126
0.254
Frequency
0.133
-0.134
Amplitude 1
0.144
Duration 1
0.124
-0.217
Slope 1
0.121
-0.213
Amplitude 2
0.220
Duration 2
-0.205
Slope 2
0.116
0.144
0.245
Power
Tumor
-0.183
distance
All p<0.01 after correction for multiple comparisons
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Table 6 – Interictal spike parameters identify seizure onset zone
Non-lesional patients
Number of patients
Number of patients
with max value at
with min value at
Significant
Kruskal-Wallis
onset electrode
onset electrode
Frequency
Yes
4
0
Amplitude 1
Yes
4
2
Duration 1
No
1
0
Slope 1
Yes
4
0
Amplitude 2
No
4
2
Duration 2
No
2
2
Slope 2
No
5
2
Power
Yes
4
0

Frequency
Amplitude 1
Duration 1
Slope 1
Amplitude 2
Duration 2
Slope 2
Power
Tumor Distance

Significant
Kruskal-Wallis
Yes
No
No
No
No
Yes
No
Yes
Yes

Lesional patients
Number of patients
with max value at
onset electrode
2
4
0
5
3
4
5
3
2

Number of patients
with min value at
onset electrode
0
2
2
0
0
0
3
0
1
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APPENDIX B
FIGURES
Figure 1 - Spike detection using filtering and block scaling balances
differences in human reviewers
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Figure 2 – Frequency and slope of the first halfwave correlate best with
seizure category in non-lesional patients
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Figure 3 – Seizure category often lies outside the tumor area, but is
identified by higher frequency and duration of interictal spiking
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Figure 4 – Setup of animal model of neocortical interictal spiking
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Figure 5 – Interictal spiking focus progresses over time
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Figure 6 – Spikes progressively cluster together with time
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Figure 7 – Expansion of spike field over time
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Figure 8 – Interictal spiking causes activity-dependent gene expression
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Figure 9 – MAPK-CREB inhibition can block the development of an
interictal spiking focus
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Figure 10 – Interictal spikes alter rat motility behavior
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Figure 11 – Interictal spikes can be induced by environmental stimuli
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Figure 12 – Suppression of interictal spiking with a MEK inhibitor
normalizes behavior
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Figure 13 – Proposed role of MAPK pathway signaling in this animal model
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APPENDIX C
FIGURE LEGENDS
Figure 1. Spike detection using filtering and block scaling balances differences in
human reviewers.

(A) Flowchart overview of the detection algorithm.

(B) The

algorithm’s main initial screening step involves bandpass filtering the data from 20-50Hz
(bottom), which makes interictal spikes (blue arrows) stand out from background
compared to more standard viewing filters (top). This method accentuates both large,
obvious spikes (left) as well as those that may have otherwise been lost in larger slow
wave background activity (right). (C) Scaling all channels together as a block preserves
differences in spike detection (blue triangles) between more and less active channels.
Typical methods of scaling each individual channel leads to undermarking of active
channels and overmarking of less active channels (red squares). (D) Heatmaps of
interictal spike frequency superimposed on a patient’s 3-dimensional brain rendering
show that the three human reviewers rank channels similarly, but not identically (top).
The spike detection algorithm, however, balances reviewer discrepancies and produces a
similar pattern to the average of all three human reviewers (bottom).

Figure 2 – Frequency and slope of the first halfwave correlate best with seizure
category in non-lesional patients. Cortical areas of seizure onset (red) and seizure
spread (yellow) can best be distinguished from normal areas of brain (green) in nonlesional patients by higher interictal spike frequency and slope of the first halfwave, as
demonstrated in this example patient. Other parameters, such as duration of the first
halfwave, are not as reliably associated with seizure-generating areas. (Colored scale bar
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shows that for each parameters, high values are colored red, intermediate values are
yellow and low values are green.)

Figure 3 – Seizure category often lies outside the tumor area, but is identified by
higher frequency and duration of interictal spiking.

In most lesional patients

(n=7/11), areas of seizure onset (red) lie outside of the immediate tumor area and may not
be resected as part of a normal tumor resection, as shown in this example patient. The
tumor is highlighted as a large, red mass within the temporal lobe. In contrast to nonlesional patients, interictal spike frequency is not the best marker for tumor area. Instead,
duration of the second halfwave is much more reliable. Spike frequency is inversely
correlated with distance from tumor, suggesting that low spike frequencies may aide in
identifying tumor margins. (Colored scale bar shows that for each parameters, high
values are colored red, intermediate values are yellow and low values are green.)

Figure 4 – Setup of animal model of neocortical interictal spiking. Three electrodes
are placed over each hemisphere, and one over the nasal sinus as a reference (circles).
Tetanus toxin is injected under the left, middle electrode (red circle) into the
somatosensory cortex. Spikes are initially detected at the injection site in the left, middle
electrode (L2), as shown by a small example segment of EEG recorded at each of the six
channels.

Figure 5 – Interictal spiking focus progresses over time. (A) A single injection of
tetanus toxin causes interictal spikes to develop after a delay of three to five days, which
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then increase in frequency with time (n=11 animals). Vehicle animals (n=5) show very
little spiking and do not change with time. Tetanus-injected animals have higher spike
frequency than vehicles by the first week (p=0.029, one-tailed t-test, Bonferroni
correction; 79.1±18.1 and 9.4±2.9 spikes/ hour, ± sem), which persists at two weeks
(p=0.020, one-tailed t-test, Bonferroni correction; 101.3±19.5 and 9.5±2.9 spikes/ hour, ±
sem) and three weeks (p=0.040, one-tailed t-test, Bonferroni correction; 178.33±45.3 and
8.6±4.2 spikes/hour±sem) (B) Tetanus-injected animals also initially increase in
amplitude, which then plateaus by 10 days (Best fit model: y=a*xb+c; R2=0.667). (C)
Spike slope increases with time (R2=0.530; Linear regression slope=0.307μV/day,
p=0.0004), while duration does not change much (R2=0.148; Linear regression slope=0.299ms/day, p=0.104). (D). Error bars are standard error of the mean.

Figure 6 – Spikes progressively cluster together with time. Example EEG samples
from the same rat show that spikes initially appear as single, isolated discharges in the
first week. By the second week, ‘doublets’ become increasingly common, and by three
weeks longer runs of three to six spikes occur. Quantifying this increase by calculating
the percent of spikes in a recording that occur clustered with other spikes shows a
progressive increase in clustering with time. (n=11; R2=0.492; Linear regression
slope=0.75%/day, p=0.0025)

Figure 7 – Expansion of spike field over time. (A) Sample EEG traces from a rat
which develops spikes predominantly in the left middle (L2) and anterior (L1) channels.
(B) Heatmap plots of the average amplitudes of spikes in each recording channel over
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time show the progression in both amplitude and distribution over time. Similarly,
example EEG traces (C) and heatmaps (D) show one of the rats which developed rightsided spikes, despite injection of tetanus toxin on the left.

Averaging the field

distribution of 11 rats over time (E) shows that spikes begin initially at the injection site,
but soon spread anteriorly and sometimes contralaterally over time. No rats showed
spread to posterior channels.

Figure 8 – Interictal spiking causes activity-dependent gene expression. Coronal
brain sections near the injection site show changing patterns of activity-dependent gene
expression with time via

35

S in situ hybridization. An animal sacrificed after one week

shows an interesting pattern of increased expression at the injection site, with an annulus
of suppression surrounding it. While Egr1 shows this most robustly, the same pattern can
be seen in superficial layer II with both Narp and Bdnf. Gapdh shows even expression as
a non-activity-dependent control. By two weeks, animals that were sacrificed while the
spiking focus was still increasing in frequency and amplitude show increased gene
expression in layers II/III of the spiking hemisphere relative to the contralateral
hemisphere, while Gapdh expression is even. By three weeks, the spiking focus of most
rats has generally stabilized and no longer shows lateralized expression differences,
despite having focal, left-hemispheric spiking.

Surgery-naïve animals showed even

expression and antisense probes showed no detectable signal.

Figure 9 – MAPK-CREB inhibition can block the development of an interictal
spiking focus. (A) By one week after injection of tetanus toxin, most spiking animals
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(n=5/7) show Creb phosphorylation in layer II/III of the spiking hemisphere relative to
the contralateral hemisphere. To attempt to block this activation, the pharmacokinetics of
a selective MAPK inhibitor were first determined by measuring drug concentrations in
plasma (B, top) and brain (B, bottom) at multiple time points after intraperitoneal
injection. The results of this study were used to determine a dosing regimen of the
inhibitor which, when given to rats in the week following tetanus toxin injection, reduces
Creb phosphorylation by immunohistochemistry relative to animals treated with the
vehicle, DMSO (C). Rats treated with intraperitoneal injections of 25 mg/kg SL327
dissolved at 25 mg/kg in DMSO twice daily for one week after tetanus toxin injection
and then monitored for interictal spiking for four weeks showed significantly decreased
spike frequency at one week (p=0.005, one-tailed t-test, Bonferroni correction; 79.1 ±
18.2 and 7.0 ± 3.6 spikes/ hour, ± sem), 2 weeks (p=0.044, one-tailed t-test, Bonferroni
correction; 100.5 ± 27.3 and 18.0 ± 9.0 spikes/ hour, ± sem) and 3 weeks (p=0.013, onetailed t-test, Bonferroni correction; 178.3 ± 45.3 and 30.7 ± 7.6 spikes/ hour, ± sem),
suggesting that MAPK is necessary for the development of interictal discharges (D).
Scale bars = 10μm(A,C).

Figure 10 – Interictal spikes alter rat motility behavior (A) Monitoring open field
activity immediately after recording EEG shows that tetanus treated spiking rats are
consistently hyperactive relative to sham-operated controls (n=4 tetanus, 4 sham; 1 week
p=0.082, 2 weeks p=0.079, 3 weeks p=0.0005, Bonferroni correction). (B) Left versus
right spike frequency ratio correlates with the ratio of counter-clockwise to clockwise
rotations rats make (R=0.396, p=0.013).

Similarly, total spike power correlated
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positively with ambulatory distance (R=0.350, p=0.039 Bonferroni correction) and
negatively with resting time (R=-0.410, p=0.008 Bonferroni correction). Values within
each rat were normalized to Z-scores before being compiled for the final correlation.

Figure 11 – Interictal spikes can be induced by environmental stimuli. (A) Study
overview: Each day of EEG recording, an audio file of a clap is played repeatedly. The
first three sounds are spaced 10 minutes apart and are then followed by a train of three
spaced one second apart. (B) A rat with spontaneous left-sided spiking has induced
spikes that appear in the same pattern on the left. EEG traces show individual examples,
while the three-dimensional heatmaps show the average of all spontaneous or induced
spikes for a particular day. (C) A rat with spontaneous right-sided spiking has induced
spikes on the right. All rats showed induced spikes in the same field distribution as the
rat’s spontaneous spikes. (D) The amplitude of induced spikes increased over time as
each rat’s spontaneous spikes increased in amplitude.

The scatter plot shows the

amplitude of induced spikes versus the amplitude of spontaneous spikes, normalizing the
values within each rat so that the highest value is 100%. (R=0.535, p=1.42x10-9). (E)
When a train of sounds only one second apart is played, EEG response to the stimulus
extinguishes rapidly, likely because rats no longer appear startled by the sound.

Figure 12 – Suppression of interictal spiking with a MEK inhibitor normalizes
behavior. Monitoring open field activity while simultaneously recording EEG shows
that tetanus treated rats increase in ambulation over time as spiking increases, but
treatment with a selective inhibitor of a component of the MAPK pathway, SL327,
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during the first week after tetanus injection prevents this increase.

Rats were

administered intraperitoneal injections of 25 mg/kg SL327 dissolved at 25 mg/kg in
DMSO twice daily for one week following surgery. By two weeks, rats given tetanus
alone ambulate significantly more than rats given tetanus and SL327 (p=0.025) and this
difference widens by week 3 (p=0.012). SL327 animals were similar to animals injected
with a vehicle solution (0.01M sodium phosphate) instead of tetanus toxin
(729.4±93.2cm; not shown).

Figure 13 – Proposed role of MAPK pathway signaling in this animal model. The
MAPK pathway can be activated both by calcium influx into the cell and by binding of
BDNF to its receptor, TrkB. Intracellular calcium can be increased by the binding of
glutamate to ionotropic glutamate receptors (AMPA and NMDA types) or by activation
of voltage-gated calcium channels (VGCC) (193). The resulting increase in intracellular
calcium (Ca2+) binds to and activates calmodulin, which in turn binds to Ras proteinspecific guanine nucleotide-releasing factor 1 (Ras-GRF1) (194,195). Ras-GRF1 acts as
a guanine nucleotide exchange factor (GEF) which causes Ras to release guanosine
diphosphate (GDP) and instead bind guanosine triphosphate (GTP), thus activating Ras.
From the TrkB receptor side, binding of BDNF to a TrkB homodimer causes
autophosphorylation of tyrosine residues in the intracellular kinase domain of the
receptor (196). Phosphorylation of a tyrosine at position 515 in the juxtamembrane region
of TrkB recruits Shc adaptor molecules through their phosphotyrosine-binding (PTB)
domains (197). The recruitment and phosphorylation of Shc adaptors leads to the binding
of growth factor receptor-bound protein 2 (GRB2) complexed with son of sevenless
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(SOS) (198) , which acts as a GEF to activate Ras to the GTP-bound form (199). Active
Ras then phosphorylates mitogen-activated protein kinase (MEK), which in turn
phosphorylates extracellular signal-regulated kinases 1 and 2 (200).

ERK can both

translocate to the nucleus and phosphorylate cytosolic ribosomal S6 kinase (p90-RSK)
which itself translocates to the nucleus (201-203). Once inside the nucleus, p90-RSK
phosphorylates the transcription factor, cyclic AMP response element binding protein
(CREB)(202). Nuclear ERK can also lead to CREB phosphorylation through mitogenand stress-activated protein kinase (MSK)(202).

ERK phosphorylates a variety of

additional targets, including ets-like gene1 (Elk1) shown here (133).

Genes whose

transcripts were found upregulated in this project include early growth response 1
(EGR1), neuronal activity-regulated pentraxin (NARP) and brain-derived neurotrophic
factor (BDNF). EGR1 is an immediate early gene (IEG) rapidly induced after long-term
potentiation(LTP)-inducing stimuli (204). EGR1 is a direct target for pCREB, since the
EGR1 promoter contains binding sites for both Elk-1 and CREB, and both these proteins
were found to be phosphorylated coincident with the onset of EGR1 expression after
glutaminergic stimulation in vivo (150-152). Additionally, inhibition of the MAPK
pathway prevents phosphorylation of both these proteins, prevented EGR1 induction and
resulted in rapidly decaying LTP (133). EGR1 causes transcription of a variety of other
mRNAs, many of which are involved in synaptic plasticity (138). The control of NARP
transcription has not been well studied, but the NARP promoter contains a CREB binding
site, and NARP is an IEG upregulated in neurons by physiologic synaptic activity and by
BDNF-induced LTP (154,155). It is a pentameric protein secreted at synapses where it
clusters AMPA receptors together and mediates synaptic refinement (205-207). BDNF
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has been shown to have a functional CRE (153) and has long been known to play a role
in synaptic plasticity and LTP (137,208-211). BDNF is secreted in an activity-dependent
manner from both pre- and post-synaptic terminals and can bind to TrkB receptors on
both surfaces, leading to further MAPK pathway activation and causing modulation of
neurotransmitter signaling (212-216).
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Epilepsy is one of the most common neurological diseases, affecting up to 1% of
the world population. Epilepsy remains poorly understood and there are currently no
medications to cure it. Patients with epilepsy have both seizures as well as another type
of abnormal activity between seizures, known as interictal spikes. Interictal spikes have
thus far been poorly researched, yet growing evidence supports an important role for
them in epilepsy. In this project, we first show the high variability between reviewers in
marking interictal spikes on intracranial EEG, and then develop and test an automated
detection method to solve this problem. Next, we use this automated detection algorithm
to identify spikes on intracranial EEG in both tumor and non-tumor patients in order to
determine the best spiking parameters to identify the seizure onset zone in each group.
We then develop and characterize an animal model of chronic, neocortical interictal
spiking to test our observations previously made in human epilepsy and to have a
molecularly-accurate model on which to test new therapeutics. Finally, we show that
interictal spikes are associated with behavioral changes in this animal model and that a
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targeted inhibitor can both prevent the development of a spiking focus and normalize
behavior.
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